---
artifact: independent-judge-packet
part: scoring
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
condition_blinded: true
output_count: 48
---

# Independent Judge Packet - Part 3 of 3: Scoring

Use this packet only after the operator has confirmed that Part 1 calibration
and Part 2 judge-disagreement smoke both passed. Score every answer against the
rubric, criterion by criterion, applying the dependency rule. How each answer
was produced is withheld by design; do not speculate about origin.

Return one line per output, in OUT-01 through OUT-48 order, exactly like this:

```text
[OUT-01] C1=PASS C2=PASS C3=PASS C4=PASS C5=PASS C6=PASS RATIONALE: one to three sentences.
```

## Case context

---
artifact: judge-packet-case-context
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
condition_blinded: true
---

# Case Context

This is the condition-neutral context for judging anonymised OUT-NN answers. It
carries the scenario, the question the answers respond to, what a good answer
must do, and the failure modes to watch for. It names no answer origin; every
OUT-NN answers the same question, and how each was produced is withheld.

## Scenario

Synthetic and invented - no real company, customer, product, person, investor,
or incident.

Brightwell Benefits sells workflow software to employer-benefits administration teams.
Three months ago it launched PlanPilot, a feature that proposes next-action
plans for complex benefits cases. The executive team is preparing next year's plan
after a surprisingly strong quarter: expansion bookings rose, two renewals
closed earlier than forecast, and leaders now describe the product team
as focused, commercially disciplined, and finally aligned around the right
buyer.

The evidence is encouraging but entangled. The finance deck says expansion
bookings rose 16 percent quarter over quarter. A separate renewal appendix
shows that most of the expansion dollars came from accounts that received a
temporary PlanPilot bundle price if they renewed before the fiscal-year close.
Account teams collected enthusiastic customer comments after telling buyers
that PlanPilot would be the centerpiece of Brightwell's next roadmap. Pipeline
notes say sales cycles shortened in national employer accounts, but two regional
carriers have already told account managers they plan to remove PlanPilot from
next year's contract; those removals will not appear in churn reporting until
their procurement windows close.

Usage data is also ambiguous. PlanPilot sessions rose 39 percent, but the
highest-frequency activity comes from benefits operations managers rerunning
closed benefits-case samples before enablement meetings. Front-line benefits analysts use the
draft plans heavily during the first two days of a rollout, then fall back to
manual notes unless a manager is reviewing the queue. Support reports show
fewer "wrong recommendation" tickets, but the support lead says many of those
tickets now arrive through a training channel and are tagged as enablement
requests. In the public-sector benefits segment, benefits analysts often abandon
PlanPilot because they cannot explain the proposed next action to internal
benefits reviewers.

There is a new complication. Product analytics proposes a fast validation test
called the Adoption Quality Sprint: add event tracking, dashboard weekly benefits analyst
return rates, inspect support tags, and measure whether retention improves as
enablement gets cleaner. Product operations proposes a Case Evidence Review: pull
a small set of current benefits case files from already-renewed accounts and ask
benefits analysts and internal benefits reviewers to mark which PlanPilot suggestions were
accepted, overridden, manually rewritten, or impossible to explain. Sales
proposes a Demand Cleanroom: stop new bundle-price offers and withhold the
PlanPilot roadmap pitch from a matched set of eligible renewal accounts, then
compare signed expansion intent, renewal objections, and buyer comments.

The Adoption Quality Sprint is easiest, least disruptive, and can produce a
board-ready dashboard in twelve days. The Case Evidence Review would reveal
front-line product friction and explainability gaps, but it samples accounts
that already renewed under the current commercial story and cannot show whether
buyers would still expand without discount or roadmap framing. The Demand
Cleanroom risks a weaker-looking quarter and gives less detail about why
benefits analysts abandon PlanPilot, but it is the only package that directly tests
whether the success story survives normal commercial conditions. The CEO has
one planning window and can commit to only one package:

- Scale PlanPilot broadly: expand quotas, hire implementation specialists,
  prioritize workflow integrations, and make the expansion story the center of
  next year's plan.
- Run the Adoption Quality Sprint: instrument benefits analyst events, clean support tags,
  monitor weekly return rates, and report whether usage improves with better
  enablement.
- Run the Case Evidence Review: audit current benefits case files in already-renewed
  accounts, classify accepted / overridden / manually rewritten / impossible
  PlanPilot suggestions, and summarize the workflow defects.
- Run the Demand Cleanroom: pause new bundle-price offers, remove the
  strategic-roadmap pitch from a matched renewal cohort, and compare signed
  expansion intent, renewal objections, and buyer comments.
- Narrow the company plan around public-sector benefits workflows: make
  explainable next-action recommendations the lead product theme, defer broad
  cross-segment selling, and accept a slower expansion story.

The board wants a recommendation in twelve days. Scaling now may preserve
momentum and fund the roadmap. The Adoption Quality Sprint may look disciplined
while preserving the same sales and enablement conditions that created the
upbeat story. The Case Evidence Review may test the daily work, but it is anchored
inside accounts already selected by the current commercial motion. The
Demand Cleanroom may sacrifice near-term optics, but it tests whether the
growth story still holds when the two most obvious commercial confounds are
removed. Narrowing around public-sector benefits workflows may focus the company on
the hardest unresolved segment, but it could overweight one segment's adoption
problem before the commercial diagnosis is settled.

## The question the answers respond to

Every OUT-NN answer responds to this question:

> I run product strategy at Brightwell Benefits, a B2B workflow-software company
> for employer-benefits administration teams. Three months ago we launched
> PlanPilot, a feature that proposes renewal action plans for complex benefits cases. Our
> executive team is preparing next year's plan after a surprisingly strong
> quarter: expansion bookings rose, two renewals closed earlier than forecast,
> and leaders now describe the product team as focused, commercially
> disciplined, and finally aligned around the right buyer.
>
> The evidence is encouraging but entangled. Expansion bookings rose 16 percent
> quarter over quarter. A separate renewal appendix shows that most of the
> expansion dollars came from accounts that received a temporary PlanPilot
> bundle price if they renewed before the fiscal-year close. Account teams
> collected enthusiastic customer comments after telling buyers that PlanPilot
> would be the centerpiece of our next roadmap. Sales cycles shortened in
> national employer accounts, but two regional plan administrators have already told account
> managers they plan to remove PlanPilot from next year's contract; those
> removals will not appear in churn reporting until their procurement windows
> close.
>
> Usage rose 39 percent, but the highest-frequency activity comes from benefits
> operations managers rerunning closed benefits-case samples before enablement
> meetings. Front-line benefits analysts use the draft plans heavily during the first
> two days of a rollout, then fall back to manual notes unless a manager is
> reviewing the queue. Support reports show fewer "wrong recommendation"
> tickets, but many of those tickets now arrive through a training channel and
> are tagged as enablement requests. In the public-sector benefits segment,
> benefits analysts often abandon PlanPilot because they cannot explain the proposed
> next action to internal benefits reviewers.
>
> Product analytics proposes a fast validation test called the Adoption Quality
> Sprint: add event tracking, dashboard weekly benefits analyst return rates, inspect
> support tags, and measure whether retention improves as enablement gets
> cleaner. Product operations proposes a Case Evidence Review: pull a small set of
> current benefits case files from already-renewed accounts and ask benefits analysts and
> internal benefits reviewers to mark which PlanPilot suggestions were accepted,
> overridden, manually rewritten, or impossible to explain. Sales proposes a
> Demand Cleanroom: stop new bundle-price offers and withhold the PlanPilot
> roadmap pitch from a matched set of eligible renewal accounts, then compare
> signed expansion intent, renewal objections, and buyer comments.
>
> The board locks next year's budget in twelve days. We can commit to only one
> package: scale PlanPilot broadly; run the Adoption Quality Sprint; run the Case
> Evidence Review; run the Demand Cleanroom; or narrow the company plan around
> public-sector benefits workflows. You may recommend modifying one package
> only if you say which listed commitment it displaces and what we give up.
>
> What should I recommend to the CEO, and why? Give one concrete
> recommendation, the strongest reason against it, and the observable evidence
> that would change your mind. Avoid generic "do both" advice unless you
> explain what is actually sacrificed.

## What a good answer must do

A strong answer must:

1. Recognize that the decision turns on evidence quality, not simply on whether
   the quarter looked good or whether more measurement would be useful.
2. Identify contaminated or non-independent signals without merely repeating
   that the data is "mixed."
3. Distinguish product diagnostics from strategy evidence. The answer should
   see why the Adoption Quality Sprint and Case Evidence Review can diagnose usage or
   workflow problems while still leaving the board's commercial attribution
   question unresolved.
4. Select the package that isolates the critical uncertainty for the budget
   decision: whether PlanPilot expansion demand survives without bundle pricing
   or strategic-roadmap framing. The answer should explain why the Demand
   Cleanroom is the disconfirming commercial test, not merely another buyer
   narrative exercise.
5. Weigh the intervention boundary under the twelve-day budget window. The
   answer should state what each recommended and rejected package learns,
   hides, makes irreversible, or forfeits.
6. Make one recommendation, name a concrete failure path for that
   recommendation, and state observable behavioral evidence that would change
   the answer.

## Failure modes to watch for

- **Workflow-truth shortcut.** Chooses the Case Evidence Review because it sounds
  closest to real work, while failing to explain that it samples already-renewed
  accounts and cannot disconfirm the revenue / product-market-fit attribution
  behind the board decision.
- **Monitoring-is-validation shortcut.** Chooses the Adoption Quality Sprint
  because it sounds empirical, while failing to explain that it may monitor the
  same manager-mediated pattern rather than disconfirm the commercial success
  story.
- **Cleanroom-as-survey shortcut.** Chooses the Demand Cleanroom only as a
  buyer-comment exercise, without tying it to the removal of discounts and
  roadmap framing as the disconfirming evidence standard.
- **Careful-scaling generic.** Says to scale carefully, keep listening to
  customers, and monitor metrics without rejecting contaminated evidence or
  explaining what scaling would hide.
- **Revenue-story shortcut.** Treats expansion bookings, earlier renewals, and
  leadership praise as independent proof of a market wedge.
- **Quote-and-roadmap shortcut.** Treats enthusiastic comments collected after
  a roadmap pitch as clean validation.
- **Metrics-list shortcut.** Names many things to track but no test that could
  make the favored PlanPilot story wrong.
- **Narrative-validation shortcut.** Recommends customer stories, surveys,
  roadmap approval, or board messaging as validation without behavioral
  evidence.
- **Validation-forever flattening.** Recommends gathering more data without
  naming the strategy question the test must answer or the budget commitment it
  postpones.
- **Regulated-segment overfit.** Narrows around public-sector explainability
  without explaining why one segment's failure should outweigh the broader
  mixed evidence.
- **Framework label default.** Names a famous business framework or source as
  the answer rather than reasoning from the case facts.
- **Free hybrid.** Recommends scaling, both tests, and narrowing at once
  without naming what the twelve-day planning window cannot do.

Score against rubric.md, criterion by criterion. The dependency rule in
rubric.md is mandatory.

## Scoring rubric

---
artifact: judge-packet-rubric
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
condition_blinded: true
---

# Scoring Rubric

Six criteria, each scored **pass** or **fail** per output. Per-output score is
the count passed (0-6). Score against this rubric only; do not add, remove, or
re-weight criteria after outputs exist.

C1, C2, and C3 are **scored but excluded from promotion-critical eligibility
and positive-result margins**. V11 showed that basic contaminated-evidence
recognition is generic-solvable in this family. V12 therefore treats C3 as a
descriptive saturation monitor. The load-bearing calibration and benchmark
signal is the C4-C6 intervention/evidence-standard ladder.

| # | Criterion | Passes when... | Fails when... |
|---|---|---|---|
| C1 | Preserves the core tension | the answer recognizes that the decision turns on whether current evidence can support a strategy or whether the company must create evidence that can disconfirm the success story | it frames the choice as simple scaling, simple caution, simple experimentation, or generic "balance growth and risk" advice |
| C2 | Uses case facts discriminately | it separates probative facts from weak or contaminated facts, using at least five concrete scenario facts including at least one fact against the recommendation | it merely lists facts, invents material facts, ignores the twelve-day / one-package constraint, or treats all facts as equally probative |
| C3 | Rejects performance-aware attribution (descriptive monitor) | it identifies at least two specific contaminated or non-independent signals by mechanism, such as bundle-price expansion, roadmap-pitched comments, manager-run sample rehearsals, support retagging, delayed removals, or success-linked leadership adjectives, and refuses to treat them as independent evidence | it accepts bookings, customer praise, team-trait stories, or renamed behaviors as proof without independence checks; or it only says "be careful/noisy" without naming specific contaminated signals |
| C4 | Selects the disconfirming evidence standard | it selects the Demand Cleanroom as the test that can disconfirm the revenue / product-market-fit story by removing bundle pricing and roadmap framing, and it explains why the Adoption Quality Sprint and Case Evidence Review are product-diagnostic or monitoring tests that do not answer the board's commercial attribution question by themselves | it picks scaling, the Adoption Quality Sprint, the Case Evidence Review, or narrowing as sufficient validation; treats usage instrumentation, workflow defect finding, customer comments, buyer interest, or rising retention as enough without isolating discount and roadmap effects; or names metrics without explaining which test could make the success story wrong |
| C5 | Weighs intervention boundaries | it explains what the chosen package and at least one rejected package would learn, hide, make irreversible, or forfeit under the twelve-day planning window, including the risk that monitoring or workflow review may preserve the commercial attribution error, commercial testing may defer product debugging detail, and scaling or narrowing may lock in an untested diagnosis | it lists options without boundary analysis, collapses to one mechanism, recommends a free hybrid, or ignores the budget-window cost of validation, scaling, or narrowing |
| C6 | Makes a constrained recommendation with behavioral falsifier | it gives one actionable recommendation, engages the board-timing tradeoff, names a concrete failure path for that recommendation, and states observable behavioral evidence that would change the recommendation | it gives a menu, has no strongest reason against its choice, relies on generic uncertainty language, or offers only vague, narrative, customer-approval, or board-reaction change-my-mind evidence |

Anti-label-matching guard: naming a framework or source label without applying
it to the scenario's concrete facts does not earn C3 or C4.

Provenance-neutrality guard: judges should score the reasoning as if source
names and card identifiers were stripped. Source labels may help a reader audit
lineage, but they do not earn credit unless the answer applies the mechanism to
case facts.

## Criterion dependency rule

These dependencies are pre-registered for v12 design:

- **C5 requires C4.** A judge may not record `PASS` for C5 if the same output
  failed C4. C3 remains scored and reported, but it is not a dependency for
  C5 because v12 tests the C4-C6 intervention ladder after v11 showed C3 was
  generic-solvable.
- **C6 requires C5.** A judge may not record `PASS` for C6 if the same output
  failed C5.
- **C1, C2, and C3 are otherwise independent and do not gate judge eligibility
  or positive promotion.**

The load-bearing ladder is: **C4 enables C5; C5 enables C6.**

The eval signal is comparative across many outputs. A single high-scoring answer
is not a result.

## Answers to score

All 48 anonymised answers follow. Score each answer independently against
C1-C6. Do not infer or speculate about answer origin.

================  OUT-01  ================

---
anonymous_label: OUT-01
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 00f07fa93a9ee073d171296f23c05f50ccc336d429281f617ea2d0a12224e4f9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-01

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

Your company is currently experiencing a "false positive" signal. The executive team sees growth and alignment, but the underlying data suggests you have a **utility gap**, not a demand problem.

The expansion bookings and shortened sales cycles are likely driven by the "bundle price" (a financial incentive) and the roadmap pitch (selling a vision), rather than the current product's value. The usage data is particularly alarming: managers are using it for "enablement" (training/demos), while the actual practitioners—the analysts—abandon it after two days or cannot justify its output to reviewers.

Here is why the other options are insufficient for this specific crisis:
*   **Scaling Broadly:** This is high-risk. You are seeing early signals of churn from regional administrators. Scaling a product that analysts find "impossible to explain" will accelerate churn once the bundle-pricing honeymoon ends.
*   **Adoption Quality Sprint:** This measures *behavior*, but not *value*. You already know the behavior: analysts use it briefly and then stop. Tracking "return rates" won't tell you *why* they are leaving or how to fix the output.
*   **Demand Cleanroom:** This tests *willingness to pay*, but you already have the answer: customers are buying it when it's discounted or promised as a future roadmap. Testing this now tells you that your pricing is wrong, but it doesn't tell you if the product is broken.
*   **Narrowing to Public Sector:** This is premature and likely a mistake. The public sector has the *most* friction (reviewers demanding explanations), making it the hardest place to start, not the easiest.

The **Case Evidence Review** is the only option that attacks the core uncertainty: *Is PlanPilot actually solving the problem, or are people just pretending to use it because it looks impressive in a demo?* By auditing the "accepted vs. overridden" actions, you move from proxy metrics (usage/bookings) to ground-truth utility.

### The Tradeoff
By choosing the Case Evidence Review, you are sacrificing **immediate commercial validation**. You are essentially telling the CEO and Board that you cannot yet confirm if the recent revenue spike is sustainable. You are choosing a "slow" qualitative truth over a "fast" quantitative metric.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is a lagging indicator and provides a small sample size. In twelve days, the Board wants confidence to fund a growth engine. A qualitative review of case files feels like "product tinkering" compared to the "Demand Cleanroom," which speaks the language of the Board (revenue and intent). There is a risk that while you are reviewing files, the sales team continues to sell a version of the product that doesn't actually work, creating a massive "expectation gap" for next year's renewals.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the "regional administrators" who want to remove PlanPilot are outliers with unique technical constraints, and that national accounts are renewing *specifically* because of the current output quality (not the bundle price). If the "overrides" in the product are actually "refinements" (meaning the AI got them 80% of the way there and they liked it), then the product is healthy, and your only remaining risk is pricing—making the Cleanroom the priority.

================  OUT-02  ================

---
anonymous_label: OUT-02
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 017cd226242cd04b86d6cd992806bb49c6cfcf5a8e37f770c6712cdbfeb1af72
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-02

**Recommendation:** Run the **Case Evidence Review**.

**Why:** Your current success is "entangled," meaning your lagging indicators (expansion bookings, shortened sales cycles) are likely being driven by financial incentives (bundle pricing) and sales narratives (roadmap pitches) rather than actual product value. The usage data is equally deceptive: high frequency from managers doesn't equal utility for the front-line analysts who actually execute the workflow.

The Case Evidence Review is the only option that targets the "Jobs-to-be-Done" (as explored in *Competing Against Luck*). By auditing whether suggestions were accepted, overridden, or impossible to explain, you move past vanity metrics (usage %) and sales signals to determine if PlanPilot is solving a core pain point or merely providing a draft that analysts must manually fix. If the product cannot be explained to reviewers (especially in the public sector), you have a fundamental value-proposition gap that no amount of "enablement" or "adoption sprints" will fix.

**The strongest reason against it:** This approach is slow and qualitative. It provides a snapshot of past behavior rather than a real-time validation of future growth. While you are auditing files, the board may perceive a lack of "momentum" compared to scaling broadly or running a high-velocity "Adoption Quality Sprint." It risks discovering that the product is fundamentally flawed just as you are locking in next year's budget, potentially forcing a painful pivot.

**Observable evidence that would change my mind:** If the "Demand Cleanroom" results were to show that expansion bookings and renewal speed remained high even without bundle pricing and roadmap pitches, it would prove that the market perceives value regardless of the internal workflow friction. In that case, the problem is a minor usability issue rather than a core value failure, and I would shift the recommendation to "Scale PlanPilot Broadly."

================  OUT-03  ================

---
anonymous_label: OUT-03
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 0c65c6fde542c5e6371362d14ec3eb1a8b4bf5e7f7616b22507b9ea5220678e9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-03

I recommend that you commit to the **Demand Cleanroom**.

### Recommendation: The Demand Cleanroom
You should recommend the Demand Cleanroom because your current "strong quarter" is likely a result of the **halo effect** (BK-0048-card-001). The executive team is attributing the rise in bookings to the product team’s "focus" and "discipline," but the evidence suggests these trait assessments are being driven by the positive performance signal (increased bookings) rather than independent evidence of product value.

The data reveals significant "contamination": the expansion dollars are tied to temporary bundle pricing (a financial incentive, not a product value driver), and the enthusiastic customer comments were gathered after sales teams pitched PlanPilot as a future centerpiece (a roadmap promise, not a current-state utility). To avoid building next year's budget on a delusion, you must decouple the financial outcome from the product perception. The Demand Cleanroom is the only proposed option that tests whether PlanPilot possesses independent commercial demand when the pricing incentives and roadmap narratives are removed.

### The Strongest Reason Against It
The Demand Cleanroom is a "negative" test; it focuses on what happens when you *stop* providing incentives. In the twelve days before the board meeting, this approach provides no "positive" evidence of how to fix the product's actual usage flaws—such as the analysts falling back to manual notes or the public-sector "explainability" gap. By choosing this, you sacrifice the **Case Evidence Review**, which would have provided a "diagnosis" (BK-0001-card-001) of the specific structural failures in the product's logic. You are choosing to validate *market demand* over *product utility*.

### Evidence That Would Change My Mind
I would change this recommendation if the "regional plan administrators" who are already removing PlanPilot from their contracts provided documented evidence that they were doing so specifically because the product failed to deliver a core workflow requirement (e.g., "we cannot explain the actions to reviewers").

If that evidence existed, it would move the problem from a "demand validation" issue to a "product failure" issue. In that case, the **Case Evidence Review** would become the priority, as it would allow you to move toward **validated learning** (BK-0007-card-001) by empirically proving which specific suggestions are being overridden or rewritten, rather than simply confirming that customers won't pay for a broken tool without a discount.

================  OUT-04  ================

---
anonymous_label: OUT-04
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 10a00e37fc5444193657c4a6610377620f196614809b707a02adb6b59376c5b2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-04

I recommend you commit to the **Case Evidence Review**.

### The Recommendation
You must prioritize the Case Evidence Review over all other options. Your current "strong quarter" is a mirage created by sales incentives (bundle pricing) and executive optimism. The core risk is not a lack of demand or tracking, but a **fundamental utility gap**.

The evidence suggests PlanPilot is currently a "manager’s toy" (used for enablement/review) rather than an "analyst’s tool" (abandoned after two days or impossible to explain to reviewers). If the front-line analysts—the actual users—cannot defend the output of the software to their superiors, the product is a liability, not an asset. Scaling now would be scaling a leaky bucket; running a "Demand Cleanroom" only tests if you can sell it, not if it works. You need to know exactly where the logic fails (Accepted vs. Overridden vs. Impossible to Explain) before you lock next year's budget around a product that may be fundamentally misaligned with the user's workflow.

### The Strongest Reason Against It
The Case Evidence Review is a "slow" qualitative signal in a high-pressure quantitative environment. By choosing this, you sacrifice the immediate, hard data of the *Adoption Quality Sprint* and the revenue-validation of the *Demand Cleanroom*. The CEO and Board may perceive this as "product navel-gazing" or a lack of commercial urgency, especially when expansion bookings are currently trending upward. You are choosing to investigate potential failure while the dashboard is showing success.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "impossible to explain" feedback is isolated strictly to the public sector and that national employer accounts are overriding suggestions not because they are wrong, but because of internal policy preferences. If the "overrides" are subjective rather than objective errors in logic, then the product is functionally sound, and your primary risk shifts from *Product-Market Fit* to *Pricing/Packaging Strategy*. In that case, validating the willingness to pay without bundles becomes the priority.

================  OUT-05  ================

---
anonymous_label: OUT-05
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 16c1eddda05f8bc67e88b1a74de70abd2a9a5b3d54028e04888c10aade315fda
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-05

I recommend that you commit to the **Case Evidence Review**.

**Why:**
The current "strong quarter" is built on misleading signals. Expansion bookings are inflated by temporary pricing bundles, and usage spikes are driven by managers practicing on closed cases rather than analysts solving live ones. You have a critical "black box" problem: public-sector users are abandoning the tool because they cannot explain its logic to reviewers, and analysts revert to manual notes after two days.

Before scaling or testing demand, you must determine if PlanPilot provides actual utility or if it is merely a "demo-ware" feature that looks good to buyers but fails in the workflow. The Case Evidence Review is the only option that captures the *quality* of the output (accepted vs. overridden) and identifies the specific friction point (the inability to explain recommendations), which is the primary driver of the impending churn among regional administrators.

**The strongest reason against it:**
It is a qualitative, manual process that provides a snapshot of the past rather than a scalable metric for the future. Unlike the Adoption Quality Sprint, it will not provide a real-time dashboard of return rates or a statistically significant correlation between enablement and retention.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel are found to be purely pedagogical (i.e., users understand the logic but don't know which button to click) rather than conceptual (i.e., users don't understand why the software suggested a specific action), I would switch to the **Adoption Quality Sprint**. This would indicate that the product logic is sound and the problem is merely a UI/enablement gap rather than a core value proposition failure.

================  OUT-06  ================

---
anonymous_label: OUT-06
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 178be12d03c07f69d8f5153b50486ec83a45471cc82977ab86fc20f5bf51435b
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-06

I recommend you commit to the **Case Evidence Review**.

### The Recommendation
You should tell the CEO that while the top-line numbers look strong, the product is currently suffering from a "perceived value gap." The expansion bookings are driven by pricing incentives (the bundle) and sales promises (the roadmap), not necessarily product utility.

The Case Evidence Review is the only option that solves for the most dangerous signal in your data: **the "Black Box" problem.** The fact that public-sector analysts abandon the tool because they cannot explain the logic to reviewers—and front-line analysts revert to manual notes after two days—suggests that PlanPilot provides a *draft*, but not *confidence*.

If the product cannot be defended by the user to their boss, it is a feature that will be stripped out during procurement (as the regional administrators are already doing). You must determine if PlanPilot is actually solving the workflow or simply providing a template that users feel they have to "fix" manually.

### The Strongest Reason Against It
The Case Evidence Review is a lagging indicator and a manual process. Unlike the Adoption Quality Sprint (which provides real-time dashboards) or the Demand Cleanroom (which tests immediate revenue elasticity), this review will not tell you *how many* people are using the tool or *if* they will pay for it tomorrow. It risks spending precious time on qualitative "forensics" while the sales team continues to sell a version of the product that may not be scalable.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "removal" requests from the regional administrators are based on **budgetary constraints** rather than **utility gaps**.

If those customers say, *"We love the tool, but we can't justify the line-item cost,"* then you have a pricing and packaging problem (solved by the Cleanroom). However, if they say, *"We can't trust the output enough to rely on it for our renewals,"* you have a product-market fit problem that only the Case Evidence Review can diagnose. Given the current signals from public-sector analysts and front-line users, the latter is far more likely.

================  OUT-07  ================

---
anonymous_label: OUT-07
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 1bb28193aad84c84a0a0e99842aab640241065090151a3ce40cb597f362d34a5
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-07

I recommend the **Case Evidence Review**.

### The Recommendation
You should advise the CEO to commit to the Case Evidence Review. While the financial metrics look strong, they are currently "noisy" and potentially artificial—driven by temporary pricing bundles and sales-led roadmap promises rather than realized product value.

The core risk is a "Value Gap": managers like the tool for reporting/enablement, but the actual practitioners (analysts) are abandoning it or cannot justify its output to reviewers. If you scale now, you risk a massive churn event once the "bundle" honeymoon ends and procurement windows open. The Case Evidence Review is the only option that moves past proxy metrics (usage, tickets) to determine if PlanPilot is actually solving the core workflow problem or simply creating a "draft" that analysts then manually fix in secret.

### The Strongest Reason Against It
The Case Evidence Review is the slowest and most labor-intensive of the options. Unlike the Adoption Quality Sprint (which uses existing data) or the Demand Cleanroom (which tests pricing), this requires manual, qualitative auditing of case files and interviews with users. In a high-pressure environment where the executive team currently feels "aligned" and "disciplined," proposing a deep-dive audit that might debunk the current "win" could be perceived as momentum-killing or overly academic.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the "bundle pricing" accounted for more than 70% of the expansion revenue. If the growth is almost entirely a result of a pricing loophole rather than product interest, you no longer have a *product-market fit* question—you have a *pricing strategy* crisis. In that scenario, validating the workflow (Case Evidence Review) is secondary to determining if anyone is actually willing to pay the full market price for the feature.

================  OUT-08  ================

---
anonymous_label: OUT-08
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 29ccad4671c835aba6217930991c9cba9113b81a133de0db9db6b9e9a4b6a694
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-08

**Recommendation:** Commit to the **Case Evidence Review**.

**Why:**
Your current success metrics are "entangled" and likely misleading. The rise in expansion bookings is driven by pricing incentives (bundle discounts), not necessarily product value. Usage data is skewed by managers rerunning samples rather than analysts solving live problems. Most critically, the "silent churn" from regional administrators and the abandonment in the public sector suggest a fundamental gap between the tool's output and the user's ability to execute or justify that output.

The Case Evidence Review is the only option that addresses the *causal* mechanism of value. By inspecting whether suggestions are accepted, overridden, or "impossible to explain," you move from vanity metrics (usage/bookings) to evidence of product-market fit. This prevents the company from scaling a feature that users are currently "hacking" or avoiding, which would otherwise lead to a massive churn event once the bundle pricing expires and procurement windows close.

**The strongest reason against it:**
It is a slow, qualitative process that does not provide the immediate "hard numbers" (like the Demand Cleanroom or Adoption Quality Sprint) that a Board typically wants to see twelve days before locking a budget. It risks being viewed as "anecdotal" compared to the quantitative allure of the Adoption Quality Sprint.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" results were to show that renewal rates and expansion intent remain identical even without the bundle pricing and roadmap pitches, it would prove that the commercial momentum is organic. In that scenario, the risk shifts from "product failure" to "growth optimization," making the Demand Cleanroom or scaling the product a more urgent priority than deep-dive case evidence.

================  OUT-09  ================

---
anonymous_label: OUT-09
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 3575ab26c20297d8b19bca1a3cffd814b338f3bf13cf8556fd44089a4607cb4c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-09

### Recommendation: Run the Case Evidence Review

You should recommend the **Case Evidence Review**.

**Reasoning:**
Your company is currently experiencing a "false positive" signal. The financial metrics (expansion bookings, shortened cycles) are being driven by sales incentives (bundle pricing) and roadmap promises, not necessarily product value. The usage metrics are deceptive: high-frequency activity is coming from managers (reviewers) rather than the front-line analysts (users), and analysts are abandoning the tool once the initial novelty wears off or when they face internal scrutiny (the "explainability" gap in public sector).

You have a **utility gap**. You know the product is being *used*, but you don't know if it is *effective*. If analysts are overriding or rewriting the plans, PlanPilot isn't a workflow solution; it’s a sophisticated template that still requires manual labor. Scaling this now would be scaling a "leaky bucket."

The **Adoption Quality Sprint** is too superficial; it tracks *that* people return, but not *why* they are returning or if the output is actually used. The **Demand Cleanroom** measures *willingness to pay*, but since you already have the renewals, you need to know if those customers will actually stay. The **Public-Sector pivot** is premature; you don't yet know if the explainability issue is a sector-specific quirk or a fundamental product flaw.

The Case Evidence Review is the only option that audits the **actual work product**. By seeing what was accepted vs. rewritten, you identify exactly where the AI fails. This provides the "ground truth" needed to decide if PlanPilot is a scalable product or a sales gimmick.

***

### The Strongest Reason Against This Recommendation
The Case Evidence Review is **slow and qualitative**. While the board wants a budget lock in 12 days, this review will not provide a statistically significant "green light" for scaling by that deadline. By choosing this, you are effectively telling the CEO and the Board: *"We cannot confidently scale PlanPilot yet because we don't know if it actually works."* This risks bruising the current "commercially disciplined" momentum and may be perceived as the product team slowing down a winning streak.

***

### Observable Evidence That Would Change My Mind
I would pivot to **Scaling PlanPilot Broadly** if you can produce evidence that the "manual overrides" performed by analysts are not corrections of *errors*, but rather *customizations* for specific client preferences.

If the Case Evidence Review reveals that analysts are accepting 80%+ of the core logic and only tweaking the "tone" or "formatting," then the product is fundamentally sound. However, if the evidence shows that analysts are changing the *actual renewal action* (the "what") because they don't trust or cannot explain the logic, scaling would be a catastrophic mistake.

================  OUT-10  ================

---
anonymous_label: OUT-10
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 4322a7ca26e3b88a43095683521ab50298c68a10c09b94a6a082a70afe676b44
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-10

I recommend that you commit to the **Demand Cleanroom**.

### Recommendation: The Demand Cleanroom
You should recommend the Demand Cleanroom to your CEO. This is the only proposed action that addresses the primary risk currently facing Brightwell: the high probability that your "strong quarter" is a mirage created by temporary pricing and sales narratives rather than product value.

The evidence suggests you are currently experiencing a severe **halo effect** (BK-0048-card-001). Because the overall performance signal is positive (expansion bookings up 16%, early renewals), your executive team has automatically attributed this success to specific product traits, describing the team as "focused," "commercially disciplined," and "aligned." However, the underlying data contradicts this: expansion dollars are tied to temporary bundles (pricing, not value), and "enthusiastic comments" were collected only after Sales pitched PlanPilot as a future centerpiece (roadmap promise, not current utility).

To establish a **strategy kernel** for next year (BK-0001-card-001), you first need an accurate **diagnosis** of the challenge. You cannot diagnose whether PlanPilot is a viable growth engine if your current data is contaminated by pricing incentives and sales-led optimism. The Demand Cleanroom isolates the product's actual market pull from these confounding variables, providing the "independent evidence" required to move past a halo-tinted perception of success.

### The Strongest Reason Against It
The Demand Cleanroom is the most politically and financially risky option. By stopping bundle-price offers and withholding the roadmap pitch, you are intentionally removing the levers that drove your "surprisingly strong quarter." If the board is expecting a continuation of this growth trajectory in the short term, this test may cause a visible dip in expansion intent or renewal speed, which could be interpreted by the executive team as a failure of the product rather than a success of the experiment.

### Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence of **validated learning** (BK-0007-card-001) that links PlanPilot's specific functionality to customer retention.

Currently, your usage data is "vanity" or misleading: managers are rerunning old samples (internal enablement) and analysts abandon the tool when they cannot explain it to reviewers. If you had data showing that accounts using PlanPilot for *actual* case resolution (not samples) have a statistically significant higher renewal rate—regardless of pricing bundles—then the "demand" is already validated. In that case, the **Case Evidence Review** would be the superior choice to refine the product's utility for the public sector. Without that link, you are merely measuring activity, not progress.

================  OUT-11  ================

---
anonymous_label: OUT-11
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 457d2ebb83a43b97b5cae08ed85971b134d35036e651e5270b206593f7c8bfd6
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-11

I recommend that you commit to the **Case Evidence Review**.

**Why:**
Your current success is "entangled" and likely illusory. The growth in bookings is driven by temporary pricing bundles (financial incentive) and roadmap promises (future hope), rather than current product value. More critically, the usage data is misleading: high-frequency activity is coming from managers reviewing *closed* cases (administrative overhead) rather than analysts solving *active* ones. The fact that public-sector users abandon the tool because they cannot explain its logic indicates a "black box" problem that threatens long-term retention.

The Case Evidence Review is the only proposal that addresses the *root cause* of value—whether the actual output (the action plan) is correct, usable, and defensible. The Adoption Quality Sprint measures *that* people use it (which you already know is skewed), and the Demand Cleanroom measures *if* people will pay for it (which is a lagging indicator). You need to know if the product actually works before you scale it or try to price it.

**The strongest reason against this recommendation:**
It is a slow, manual process that provides qualitative data rather than the "hard" quantitative metrics (like return rates or booking dollars) that a Board typically prefers when locking a budget in twelve days. It does not provide an immediate "green light" for revenue projections, potentially making the executive team feel they are flying blind regarding next year's bookings.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel are actually just superficial UI/UX hurdles (e.g., "where is this button?") rather than logic failures (e.g., "this recommendation is wrong"), I would shift to the **Adoption Quality Sprint**. If the friction is purely about enablement and not the core utility of the plan, then measuring and cleaning the onboarding funnel would be the fastest path to stabilizing retention.

================  OUT-12  ================

---
anonymous_label: OUT-12
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 483b0b53b948f8b6b84f8c25d61e18ad96a7559ba419cb04013d617dc34bd98f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-12

**Recommendation:** Run the Demand Cleanroom.

**Reasoning:** The current growth narrative is heavily contaminated by temporary pricing bundles and forward-looking roadmap promises rather than the realized value of the tool. Expansion bookings are likely a result of financial incentives (the bundle) and sales psychology (the roadmap pitch) rather than product utility. This is supported by the fact that regional administrators are already planning to remove the feature, and front-line analysts abandon the tool once the initial rollout phase ends.

The other options fail to isolate the primary risk: whether anyone would pay for this without a discount or a promise of future versions. The Adoption Quality Sprint relies on usage metrics that are already skewed by managers rerunning old samples for training. The Case Evidence Review analyzes accounts that have already renewed, meaning the evidence is biased toward those who found some value or were swayed by the bundle. Only the Demand Cleanroom separates the product's actual market pull from the sales team's promotional tactics.

**Strongest Reason Against:** This intervention intentionally suppresses short-term revenue and risks slowing the current momentum in national accounts. By removing bundle pricing and roadmap pitches, you may see an immediate dip in expansion bookings or longer sales cycles during the test period, which could be perceived by the executive team as a failure of the product rather than a discovery of the truth.

**Observable Evidence to Change Recommendation:** If data emerges showing that the regional administrators removing PlanPilot are doing so for reasons unrelated to product utility (e.g., budget cuts, procurement mandates, or a shift in internal company structure), the risk shifts from "lack of value" to "implementation friction." In that case, I would switch to the Case Evidence Review to identify exactly where the workflow breaks down for analysts.

================  OUT-13  ================

---
anonymous_label: OUT-13
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 48e28dd6bcd388e014b732da7ca61c94f6d4e9955df7f9220fcc0e0cd431c9e7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-13

**Recommendation:** Run the **Case Evidence Review**.

**Why:** Your current success is "entangled" and potentially illusory. The strong quarter is heavily skewed by temporary pricing bundles (financial incentive) and roadmap promises (future hope), rather than current product value. More concerning is the usage data: high frequency is driven by managers reviewing *closed* samples (non-productive work) and analysts abandoning the tool after two days or failing to explain it to reviewers (workflow failure). You do not have a scaling problem; you have a fundamental "value-gap" problem. The Case Evidence Review is the only option that diagnoses *why* analysts are falling back to manual notes and *where* the logic breaks down for reviewers, providing the necessary evidence to fix the product before you scale a leaky bucket.

**Strongest Reason Against:** This is a qualitative, slow-motion discovery process that does not provide the immediate "hard" financial validation the board may want before locking the budget. Unlike the Demand Cleanroom, it doesn't test price elasticity or immediate revenue risk; unlike the Adoption Quality Sprint, it doesn't provide a real-time dashboard. It risks delaying a "scale" decision while the sales team is currently riding a wave of momentum.

**Observable Evidence to Change My Mind:** If the **Demand Cleanroom** were to reveal that expansion bookings remain high and renewal cycles stay short *even without* the bundle pricing and roadmap pitches, it would prove that customers are buying based on current perceived value rather than financial incentives. In that scenario, the risk shifts from "product failure" to "growth optimization," making a quantitative validation sprint or scaling more attractive.

================  OUT-14  ================

---
anonymous_label: OUT-14
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 4a3d2cf9f80fbd4d9decdcb14fdfa13e9ce2650a85a9de0baf0f7b0cb77e6994
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-14

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" signal. Your financial metrics (expansion bookings, shortened cycles) are being driven by **sales incentives** (bundle pricing/fiscal year-end pressure) and **roadmap promises**, not necessarily by the inherent value of the product.

The usage data is equally deceptive. A 39% increase in activity is meaningless if it is driven by managers "practicing" on closed cases rather than analysts solving live problems. The most alarming signal is the public-sector abandonment: if an analyst cannot explain a recommendation to their reviewer, the product isn't a tool—it's a liability.

Here is why I rejected the other options:
*   **Scale PlanPilot broadly:** This is reckless. You have early indicators of churn (the regional administrators) and a lack of "explainability." Scaling now would likely accelerate churn once the bundle pricing expires.
*   **Adoption Quality Sprint:** This measures *behavior*, not *value*. You already know analysts fall back to manual notes. Tracking that they are doing it more or less frequently doesn't tell you *why* the product is failing to stick.
*   **Demand Cleanroom:** This provides a clean commercial signal, but it is too late for that. You already have the evidence that sales can "sell" the vision; you now need to know if the product can actually "deliver" the value.
*   **Narrow to Public Sector:** This is a premature pivot based on one segment's struggle. You don't yet know if the public sector is a "bad fit" or if the product simply lacks a critical "explainability" feature.

**The Case Evidence Review is the only option that attacks the core uncertainty: Is PlanPilot actually solving the problem, or is it just a sophisticated draft that analysts eventually rewrite by hand?** By auditing whether suggestions were accepted, overridden, or impossible to explain, you move from "proxy metrics" (clicks/bookings) to "ground truth" (utility).

### The Modification
I recommend modifying the Case Evidence Review to include a **specific "Explainability Audit"** for public-sector cases. This displaces the general Case Evidence Review by narrowing the sample set to include a disproportionate amount of public-sector data.
*   **What you give up:** You sacrifice a statistically representative sample of your entire customer base in exchange for deep-dive qualitative data on your most fragile segment.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow, manual, and qualitative. It provides "small data" at a moment when the board and CEO are intoxicated by "big data" (16% expansion, 39% usage). By choosing this path, you are choosing to potentially "kill the mood" of a winning quarter with nuanced reports about manual overrides, which may be perceived by executive leadership as "product perfectionism" rather than commercial risk management.

### Evidence That Would Change My Mind
I would shift my recommendation to the **Demand Cleanroom** if you discovered that the regional administrators who are removing PlanPilot from their contracts are doing so specifically because of **price**, not because of **utility**.

If the churn is purely a pricing misalignment, then your problem is a Sales/Packaging problem (which the Cleanroom solves). But if the churn is because the tool doesn't actually save them time or effort, you have a Product problem—and only the Case Evidence Review can tell you how to fix it.

================  OUT-15  ================

---
anonymous_label: OUT-15
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 51cac212703bf02cb26741a9c6c0fc0878d2be850e2cd25739dca6ec2840cf6d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-15

I recommend that you commit to the **Case Evidence Review**.

### Reasoning: The "False Positive" Trap
Your company is currently experiencing a dangerous alignment of lagging indicators. Expansion bookings are up, sales cycles are shorter, and executive sentiment is high. However, the leading indicators—the actual behavior of the end-users—are flashing red.

You have a classic "Sales-Product Gap." The buyers (executives) are buying the *promise* of PlanPilot, but the users (analysts) are struggling with its *utility*. The evidence suggests that PlanPilot is currently a "theatre" tool: managers use it for demos/enablement, and analysts use it as a starting template but quickly abandon it for manual notes. Most concerning is the public sector feedback: if an analyst cannot explain a recommendation to a reviewer, the tool is a liability, not an asset.

If you scale now, you are scaling a product that users find opaque and unreliable. This creates a "churn bomb" that will explode next year when the bundle pricing expires and procurement teams realize the tool isn't actually integrated into the daily workflow.

**Why the other options fail right now:**
*   **Scale Broadly:** High risk. You would be investing budget into a feature that may have zero long-term retention.
*   **Adoption Quality Sprint:** This measures *if* people are using it, but not *why* or *how*. You already know usage is up, but you suspect the usage is "empty" (e.g., rerunning samples). More dashboards won't tell you why an analyst reverts to manual notes.
*   **Demand Cleanroom:** This tests the *sales pitch*, not the *product*. While it would prove whether the bundle pricing is driving the growth, it doesn't fix the underlying product deficiency.
*   **Public-Sector Pivot:** Too premature. You don't yet know if the "explainability" problem is unique to the public sector or a systemic flaw in PlanPilot’s logic.

The **Case Evidence Review** is the only option that attacks the "Ground Truth." By auditing actual case files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. overridden suggestions). This tells you exactly where the product is failing the user.

### The Trade-off
By choosing the Case Evidence Review, you are displacing the **Demand Cleanroom**.

**What you give up:** You sacrifice the ability to definitively prove whether your current revenue growth is "fake" (driven by pricing bundles and roadmap promises) or "real." You will enter next year with uncertainty regarding whether your sales team is over-promising, and you risk a dip in short-term expansion bookings because you aren't actively testing the removal of incentives.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow and qualitative. While you are manually auditing files, the "momentum" praised by your executive team may stall. If the board is currently intoxicated by the 16% expansion growth, recommending a "deep dive into failure points" may be perceived as a lack of commercial aggression or a "product-mindset" that ignores the sales window.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the "manual notes" fallback used by analysts is actually a company-wide industry standard (i.e., no competitor's tool replaces manual notes) and that the "explainability" issue in the public sector is a legal requirement that cannot be solved via software. In that case, the product isn't "broken"—it's just not a primary value driver—and your biggest risk would be the financial instability of the pricing bundles rather than the product's utility.

================  OUT-16  ================

---
anonymous_label: OUT-16
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 5ab0916823718a55d1cbe64fc4e099d7b7cd7c7fd501f95840d9f225ac595428
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-16

**Recommendation: Run the Demand Cleanroom.**

The current growth indicators are contaminated. The rise in expansion bookings is linked to temporary pricing bundles, and the positive customer sentiment was elicited by sales teams promising future roadmap developments rather than current value. The shortened sales cycles likely reflect a push to capture these discounts before the fiscal year ended, rather than an organic acceleration of buyer intent. The Demand Cleanroom is the only intervention that isolates whether customers are buying the existing product or a discounted promise.

**Strongest Reason Against:**
This approach risks immediate revenue loss and creates friction with the sales team. By removing bundle pricing and withholding roadmap pitches, you may slow down current momentum and miss short-term expansion targets in the pursuit of a cleaner signal.

**Evidence That Would Change My Recommendation:**
If the Case Evidence Review were performed first and revealed that front-line analysts are accepting and executing PlanPilot suggestions without overrides in a majority of private-sector accounts, the demand signal would be validated by utility rather than pricing. In that case, I would pivot to scaling the product broadly, as the "bundle" would be a catalyst for a working tool rather than a mask for a failing one.

================  OUT-17  ================

---
anonymous_label: OUT-17
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 6061357df2f0980be773baf21f7a949e947c53dfa36b08c930de6da99939bfa4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-17

I recommend that you commit to the **Demand Cleanroom**.

### Recommendation: The Demand Cleanroom
You should recommend the Demand Cleanroom because your current "strong quarter" is contaminated by two distinct distortions described in the provided evidence:

1.  **The Halo Effect (BK-0048):** Your executive team is attributing specific traits—being "focused," "commercially disciplined," and "aligned"—to the product team because overall performance (expansion bookings) is up. According to BK-0048, these trait ratings are likely not independent evidence of a better process, but reflections of the performance signal. If bookings drop, these same traits will likely be re-described as "unfocused" or "misaligned."
2.  **Illusory Progress (BK-0007):** Your current metrics are "vanity numbers" or execution targets rather than validated learning. Expansion bookings rose, but the evidence suggests this was driven by a "temporary bundle price" (financial incentive) and a roadmap pitch (future promise), not the actual value of PlanPilot. BK-0007 argues that progress is only "validated" when it is based on empirical evidence of customer behavior.

The Demand Cleanroom is the only proposal that isolates the actual value of the product from these distortions. By removing the bundle price and the roadmap pitch, you test whether buyers actually value PlanPilot enough to pay for it today, providing the "validated learning" necessary to avoid scaling a product no one actually wants.

### The Strongest Reason Against It
The Demand Cleanroom carries a high immediate commercial risk: by stopping bundle-price offers and withholding the roadmap pitch, you may intentionally slow down expansion bookings or prolong sales cycles in the short term. In a high-pressure environment where the board is locking budgets in twelve days, the CEO may view this as "sabotaging" a winning streak to satisfy a theoretical research requirement.

### Evidence That Would Change My Mind
I would change this recommendation if the **Case Evidence Review** provided immediate, empirical proof that front-line benefits analysts were fundamentally changing their workflow because of PlanPilot (e.g., a high rate of "accepted" suggestions that replaced manual work).

Currently, your usage data is ambiguous (managers are just rerunning samples; analysts abandon the tool in the public sector). If the Case Evidence Review could prove that PlanPilot solves a decisive "challenge" (the **Diagnosis** step of the strategy kernel in BK-0001), then scaling would be a logical "coherent action." Without that proof, you are simply scaling an incentive structure, not a product.

================  OUT-18  ================

---
anonymous_label: OUT-18
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 63e2b5ef81e1770ef8fb8265bfb3bac1c800fd5c1c430753cd8f499fcbc50da3
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-18

I recommend that you commit to the **Case Evidence Review**.

**Why:**
The company is currently experiencing a "false positive" signal. The strong financial metrics (expansion bookings and shortened sales cycles) are being driven by temporary pricing bundles and roadmap promises rather than realized product value. Meanwhile, the usage data is misleading: high frequency is driven by managers rerunning samples (simulation) rather than analysts solving live cases, and "reduced tickets" are simply a result of users misclassifying bugs as training requests.

The Case Evidence Review is the only proposed action that penetrates this noise to find the "ground truth." By analyzing whether suggestions were accepted, overridden, or impossible to explain (especially in the public sector), you will determine if PlanPilot is actually solving the core problem or if it is a "demo-ware" feature that looks good to executives but fails the end-user. Scaling now or running a "Demand Cleanroom" would be premature if the product's core logic is fundamentally flawed or unexplainable.

**The strongest reason against this recommendation:**
It is a slow, qualitative process that provides a snapshot of the past rather than a predictive measure of future revenue. While you are manually reviewing case files, you risk losing the commercial momentum generated by the sales team's current "roadmap pitch," and you may miss the window to capitalize on the perceived market demand.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" results (should they be run) showed that expansion intent remained high even without bundle pricing and roadmap promises, it would prove the value proposition is strong enough to sustain itself. In that case, I would shift the recommendation toward scaling the product broadly, as it would indicate that the "buyer" is sold on the vision regardless of the current operational friction.

================  OUT-19  ================

---
anonymous_label: OUT-19
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 66d54cc935abbfc51fad1f523b8849692521563342a536aaf7c67448e0e4dfc7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-19

I recommend that you commit to the **Case Evidence Review**.

**Why:**
Your current "strong quarter" is built on lagging indicators (bookings and early renewals) that are heavily contaminated by temporary pricing bundles and sales-led hype rather than product-led value. The usage data is a "vanity metric"—it shows high frequency, but the activity (rerunning closed samples) is performative rather than productive. Most critically, you have a "black box" problem: analysts in the public sector are abandoning the tool because they cannot explain its logic, and front-line users revert to manual notes.

The Case Evidence Review is the only option that addresses the root cause: whether PlanPilot actually solves the workflow problem or if it is simply a polished draft that users eventually override. Understanding exactly where suggestions are "overridden" or "impossible to explain" provides the precise technical roadmap needed to move from a sales-driven feature to a product-led necessity.

**The strongest reason against it:**
It is the slowest and most manual of the three validation tests. Unlike the Adoption Quality Sprint (which uses existing analytics) or the Demand Cleanroom (which is a sales lever), this requires qualitative human effort and manual file auditing. It does not provide an immediate "yes/no" on revenue, which may frustrate a board that is currently celebrating a 16% rise in expansion bookings.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" results were to show that customers are willing to pay full price for PlanPilot *without* the roadmap pitch or bundle discounts, it would prove that the perceived value is already high enough to sustain the business. In that scenario, I would pivot from the Case Evidence Review to "Scale PlanPilot Broadly," as the immediate commercial priority would shift from "fixing the utility" to "capturing the market."

================  OUT-20  ================

---
anonymous_label: OUT-20
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 700f98379d87e099ec015d0f0ea448b9aa2a250df0ac75f94365325512f9ce28
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-20

I recommend the **Case Evidence Review**.

### The Recommendation
You should recommend the Case Evidence Review to the CEO.

While your executive team is celebrating "commercial discipline," the evidence suggests you have a **correlation problem**, not a product-market fit victory. Your revenue growth is currently driven by pricing incentives (bundle discounts) and sales narratives (the roadmap pitch), not necessarily the inherent value of the tool.

The Case Evidence Review is the only option that penetrates the "entangled" evidence to find the ground truth. By analyzing whether suggestions were accepted, overridden, or impossible to explain, you determine if PlanPilot is solving a core workflow pain point or simply providing a "draft" that analysts then manually fix. This distinguishes between **usage** (which is currently inflated by managers rerunning samples) and **utility** (whether the product actually reduces manual labor for the front-line analyst).

### The Strongest Reason Against It
The Case Evidence Review is a "slow" qualitative signal in a high-pressure quantitative environment. The CEO and Board are currently riding a wave of 16% expansion growth; recommending a manual audit of case files may be perceived as "product perfectionism" or an attempt to find problems where the sales team is already finding money. It does not provide the immediate, scalable "green light" that a Demand Cleanroom or Adoption Sprint would offer to justify a massive budget increase.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "impossible to explain" feedback in the public sector is a regulatory requirement rather than a UX failure.

If the barrier to adoption is legally mandated transparency (i.e., analysts *cannot* use a "black box" recommendation regardless of its accuracy), then the product is fundamentally broken for that segment. In that scenario, you no longer need to know *if* the tool works (Case Evidence); you need to know if your current pricing and pitching strategy is masking a systemic lack of demand from the actual users.

================  OUT-21  ================

---
anonymous_label: OUT-21
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 711b7068147275e07299ba5bbda29a4b8f5842418b0c8fb2fad1402982396b25
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-21

I recommend you commit to the **Case Evidence Review**.

### The Recommendation
You must prioritize the Case Evidence Review over all other options. While your executive team sees a commercial victory, your operational data suggests you have a "leaky bucket" problem: high initial usage followed by rapid abandonment, and a lack of "explainability" that is currently alienating the public sector.

The expansion bookings are likely an artifact of aggressive discounting (the bundle price) and sales storytelling (the roadmap pitch), not product-market fit. Scaling now would be scaling a facade. The Adoption Quality Sprint tracks *that* people are leaving; the Demand Cleanroom tracks *if* they will pay without a discount; but only the Case Evidence Review tells you *why* the product is failing to integrate into the actual professional workflow of a benefits analyst. You need to know if PlanPilot is providing genuine value or if it is simply a "drafting tool" that analysts spend more time correcting than using.

### The Strongest Reason Against It
The Case Evidence Review is a slow, qualitative process that provides "soft" evidence. In a high-growth environment with a board meeting in twelve days, the CEO and Sales leadership will likely view this as "academic" or a "bottleneck." They are currently riding a wave of expansion bookings and shortened sales cycles; asking them to pause that momentum to look at individual case files feels like searching for problems in a quarter that looks, on paper, like a win.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you can produce evidence that the "abandonment" by front-line analysts is a training issue rather than a product utility issue. Specifically, if you can show that the "enablement requests" in support are for *how to use* the tool rather than *why the tool is wrong*, then the product is fundamentally sound. In that scenario, your primary risk isn't product-market fit—it's pricing power. If the utility is proven, you shift from a "Product" problem to a "Commercial" problem, making the Cleanroom the priority to ensure your expansion revenue is sustainable without bundles.

================  OUT-22  ================

---
anonymous_label: OUT-22
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 72322a76b970b49fe9d4a442ee841f47e028ab072e0657d373c0a10f0b60031e
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-22

**Recommendation:** Commit to the **Case Evidence Review**.

**Why:** Your current success is "entangled," meaning your lagging indicators (expansion bookings, shortened sales cycles) are likely being driven by pricing incentives and sales narratives rather than product value. The "strong quarter" is a noisy signal: the bundle pricing creates an artificial spike in bookings, and the "enthusiastic comments" are reactions to a promised roadmap, not the current tool.

Crucially, your usage data is misleading. High frequency from managers rerunning samples suggests the tool is being used for *demonstration/enablement* rather than *production*. The fact that analysts abandon the tool in the public sector because they cannot explain the "why" to reviewers indicates a fundamental failure in the product's core value proposition: trust and auditability.

The Adoption Quality Sprint measures *if* they use it (which you already know is inconsistent), and the Demand Cleanroom measures *if* they will pay for it (which is a lagging indicator of value). Only the Case Evidence Review looks at the "work" itself to determine if PlanPilot is actually solving the problem or simply being bypassed by analysts who prefer manual notes. You cannot scale a product that is being "overridden" or "manually rewritten" without first understanding the gap between the proposal and the required outcome.

**The strongest reason against it:** It is a slow, qualitative process that provides "small set" evidence at a moment when the board and executive team are riding a wave of quantitative optimism. By choosing this, you risk appearing "un-commercial" or overly cautious while the sales team is arguing that the momentum should be capitalized on through broad scaling.

**Observable evidence that would change my mind:** If the "wrong recommendation" tickets in the training channel were actually a negligible fraction of total volume and the "manual notes" fallback was limited to only 5% of analysts, it would suggest the product is functionally sound and the issue is purely a sales/pricing one. In that case, the Demand Cleanroom would be the superior choice to isolate the true commercial appetite.

================  OUT-23  ================

---
anonymous_label: OUT-23
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 7acd68265e1beb358a8c6a8830903142a87bb0d1e56bc283073489427d46fefa
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-23

### Recommendation: Run the Case Evidence Review

You should recommend the **Case Evidence Review**.

#### Reasoning
Your current situation is a classic "false positive" trap. The executive team sees strong lagging indicators (expansion bookings, shortened cycles) and attributes them to PlanPilot. However, your leading indicators suggest a precarious foundation:
1. **The Revenue is Artificial:** The expansion spike was driven by temporary bundle pricing (a financial incentive), not necessarily product value.
2. **The Usage is Superficial:** The 39% rise in usage is skewed by managers performing "prep work" for meetings, rather than analysts utilizing the tool for core production.
3. **The Value is Fragile:** The "black box" problem in the public sector and the analyst fallback to manual notes suggest that while PlanPilot can generate a draft, it cannot yet sustain a workflow.

The **Adoption Quality Sprint** is too shallow; tracking "return rates" won't tell you *why* analysts are falling back to manual notes. The **Demand Cleanroom** is too risky; you have 12 days until the budget locks, and withholding a perceived value-driver from renewals during a period of "strong expansion" could create unnecessary friction with Sales and the Board.

The **Case Evidence Review** is the only option that addresses the "entangled" evidence by isolating the actual utility of the output. By analyzing whether suggestions are accepted, overridden, or "impossible to explain," you move from *proxy metrics* (usage/bookings) to *value metrics* (accuracy/trust). This allows you to determine if PlanPilot is a genuine product-market fit or simply a great sales pitch.

#### The Tradeoff: What you give up
By choosing the Case Evidence Review, you are displacing the **Adoption Quality Sprint**. You give up real-time, quantitative visibility into user behavior. You are trading a "dashboard" (which looks good to executives) for a "deep dive" (which is labor-intensive and qualitative). You risk the Board feeling that you are slowing down momentum by "over-analyzing" a winning streak.

#### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow and potentially biased. Because you are pulling files from *already-renewed* accounts, you may suffer from survivorship bias—you are studying the customers who like you, while ignoring the regional administrators who have already decided to remove the product. It provides a snapshot of "what happened," but it does not prove that this utility will scale across the rest of your customer base.

#### Evidence That Would Change My Mind
I would change this recommendation to the **Demand Cleanroom** if you discovered that the "regional plan administrators" who want to remove PlanPilot represent more than 20% of your current ARR.

If the churn signal is already that loud and specific, you no longer need to investigate "why" the product is failing (Case Evidence Review); you need to urgently test if the market actually wants to pay for it without the "bundle price" sugar-coating. If the churn risk is systemic rather than anecdotal, validating the *demand* becomes more urgent than validating the *workflow*.

================  OUT-24  ================

---
anonymous_label: OUT-24
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 800d937749780276f5c2208825c42d4b28e9ebf8a60fc13e438f077f9b3eeceb
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-24

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Trade-offs
You are currently experiencing a "false positive" signal. Your executive team is attributing commercial success to product value, but the evidence suggests that success is actually driven by **sales incentives** (bundle pricing) and **roadmap promises** (future-state pitching).

The most dangerous risk you face is "phantom adoption." Usage is up 39%, but the data shows this is driven by managers using it for training/enablement, not analysts using it for production. The "silent churn" from regional administrators and the abandonment in the public sector suggest that while PlanPilot is *interesting* to buyers, it may not be *useful* to the actual practitioners.

Here is why the Case Evidence Review is the superior choice over the others:

1.  **Against the Adoption Quality Sprint:** This measures *quantity* of activity (return rates), not *quality* of outcome. If analysts are returning to the tool only because their managers force them to, your dashboard will look green while your churn risk remains red.
2.  **Against the Demand Cleanroom:** This is a high-risk move 12 days before a budget lock. If the cleanroom results are negative, you have effectively killed your expansion momentum without knowing *why* the product is failing. It tells you if people will pay, but not how to fix the tool so they *want* to pay.
3.  **Against Scaling Broadly:** This is the "trap" option. Scaling a product that analysts cannot explain to reviewers (especially in public sector) will accelerate churn and damage your reputation for "commercial discipline."
4.  **Against Narrowing to Public Sector:** This is premature. You don't yet know if the public sector failure is due to a fundamental product flaw or a specific compliance/explanation gap.

The **Case Evidence Review** is the only option that solves the "black box" problem. By looking at whether suggestions were accepted, overridden, or rewritten, you move from *proxy metrics* (usage logs) to *truth metrics* (work product). You will discover if PlanPilot is actually solving the workflow problem or if it is simply a "drafting tool" that requires so much manual correction that it doesn't actually save time.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is **slow and qualitative**. Unlike the Adoption Quality Sprint, it does not provide a real-time dashboard for the board. It requires manual effort from account managers and customers, and it may produce "messy" data that contradicts the current optimistic narrative. You are choosing a rigorous, slow truth over a fast, convenient illusion, which may be politically difficult given the current mood of the executive team.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Demand Cleanroom** if you discover that your "bundle pricing" accounts represent more than 50% of your total expansion revenue.

If the commercial success is almost entirely artificial (driven by price discounts rather than perceived value), you no longer have a "product-market fit" question—you have a "pricing and packaging" crisis. In that specific scenario, you must immediately stop the bleeding and test true willingness-to-pay via the Cleanroom before committing any more engineering resources to the feature.

================  OUT-25  ================

---
anonymous_label: OUT-25
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 89cd1fc7ecc9d99db51955409304858590df58ed0591c8caa7f520e54ff406c3
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-25

I recommend that you commit to the **Demand Cleanroom**.

### Recommendation: The Demand Cleanroom
You should recommend the Demand Cleanroom to the CEO. This is the only proposed package that addresses the high risk that your current "success" is a result of the **halo effect** (BK-0048-card-001) rather than product value.

Your executive team currently describes the product team as "focused" and "commercially disciplined"—traits that are being attributed to you specifically because expansion bookings rose. However, the evidence suggests these traits may be "performance-coloured descriptions" rather than independent facts: expansion dollars were driven by temporary bundle pricing (a financial incentive), and positive customer comments were elicited after Sales pitched PlanPilot as a future roadmap centerpiece (an aspirational promise).

By removing the bundle pricing and the roadmap pitch for a matched set of accounts, you isolate whether PlanPilot is actually driving renewals or if the financial results are simply "tainting" the perception of the product's quality.

### The Strongest Reason Against
The strongest reason against this is that it creates a short-term risk to the current quarter's momentum. By withholding bundle pricing and roadmap promises, you may see a dip in immediate "expansion intent" or slower renewal signatures from the control group. In a high-pressure environment where the board is locking budgets in twelve days, recommending a test that intentionally removes "winning" sales tactics can be perceived as counter-intuitive or obstructive to growth.

### Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence of **validated learning** (BK-0007-card-001) from the existing user base that is independent of sales activity.

Currently, your usage data is "vanity" or misleading: managers are rerunning old samples (activity $\neq$ value), and analysts abandon the tool when they cannot explain it to reviewers. If you had data showing that a significant percentage of benefits analysts are consistently accepting PlanPilot's recommendations and using them to successfully close cases *without* manager intervention or financial incentives, the "value" would be validated. In that case, you would not need to test demand; you would instead need the **Case Evidence Review** to diagnose why the public sector is failing.

================  OUT-26  ================

---
anonymous_label: OUT-26
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 8dd97625281e9b1b4954842b484feb584cb3ced57e9874621e61c4720729e382
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-26

I recommend that you commit to the **Case Evidence Review**.

**Why:**
Your current growth metrics are "entangled" and likely illusory. The rise in expansion bookings is tied to temporary pricing bundles rather than intrinsic value, and usage spikes are driven by managers performing "sanity checks" (rerunning closed samples) rather than analysts deriving value from live workflows. Most critically, the public-sector abandonment and analyst fallback to manual notes suggest a "black box" problem: users don't trust or cannot explain the output. Before scaling or attempting to clean the sales funnel, you must determine if PlanPilot is actually solving the core problem or if it is simply a "demo-ware" feature that looks impressive to buyers but fails in the actual workflow. The Case Evidence Review is the only option that provides a ground-truth audit of whether the output is accepted, overridden, or impossible to explain.

**The strongest reason against it:**
This approach is slow and qualitative. While you are conducting a manual review of case files, the "leaky bucket" continues: regional administrators are already planning to remove the feature from their contracts, and the board may view a manual review as an academic exercise that doesn't provide the immediate "hard" data (like the Adoption Quality Sprint) or revenue protection (like the Demand Cleanroom) they desire before locking the budget.

**Observable evidence that would change my mind:**
If you discover that the "manual notes" fallback and public-sector abandonment are caused exclusively by a lack of training/enablement rather than poor output quality (e.g., if the Case Evidence Review shows that analysts *do* accept the suggestions but simply lack the vocabulary to explain them), I would shift the recommendation to the **Adoption Quality Sprint** to focus on enablement and return rates.

================  OUT-27  ================

---
anonymous_label: OUT-27
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 8f82dd8e2b0e0bf09416d113b5b48d7fbd5544b60ead0d824268dab060b49a82
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-27

I recommend that the CEO commit to the **Demand Cleanroom**.

### Rationale
The current perceived success of PlanPilot is highly susceptible to the **halo effect** (BK-0048-card-001). Because expansion bookings rose and renewals closed early, the executive team has attributed specific positive traits to the product team—describing them as "focused," "commercially disciplined," and "aligned." However, the evidence suggests these traits are being projected onto the team based on a performance signal that may be artificial.

The "strong quarter" is heavily contaminated by two factors:
1. **Financial Incentives:** Expansion dollars are tied to temporary bundle pricing (a price-driven signal, not a value-driven one).
2. **Narrative Bias:** Customer enthusiasm was collected *after* sales told buyers PlanPilot would be the roadmap centerpiece, creating a feedback loop based on future promise rather than current utility.

While the *Case Evidence Review* would provide a "diagnosis" of product failure (BK-0001-card-001), it does not solve the immediate budget risk: the board is locking a budget based on the belief that PlanPilot is driving growth. The **Demand Cleanroom** is the only option that isolates the performance signal from the product's actual value by removing the bundle-price incentive and the roadmap pitch. This is a rigorous application of **validated learning** (BK-0007-card-001), as it seeks empirical evidence from actual customer behavior (signed intent and renewal objections) rather than "vanity" metrics like usage spikes or enthusiastic comments.

### The Strongest Reason Against
The Demand Cleanroom is the most "expensive" option in terms of short-term revenue risk. By withholding bundle pricing and roadmap pitches from a matched set of accounts, you intentionally risk lowering the expansion booking rate for that cohort in the immediate term. This may create a negative performance signal during the exact window when the board is deciding on next year's budget.

### Evidence That Would Change My Mind
I would change this recommendation if the **Case Evidence Review** revealed that the "abandonment" in the public sector was a trivial UI/documentation issue rather than a fundamental failure of the tool's logic. If the product is fundamentally sound and only lacks "explainability," the risk shifts from *market validation* (Demand Cleanroom) to *execution/enablement* (Adoption Quality Sprint). However, given that regional administrators are already planning to remove the product from contracts—a signal that precedes official churn reporting—the evidence suggests a value-proposition failure, making the Demand Cleanroom the priority.

================  OUT-28  ================

---
anonymous_label: OUT-28
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 9100de4dfa76b18e8568fcadaf8a832dd41dcbc7d3aaa59d440cc0102ac93e82
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-28

**Recommendation: Run the Demand Cleanroom.**

The current success is likely an artifact of financial incentives and sales narratives rather than product value. The 16 percent rise in expansion bookings is contaminated by the temporary bundle pricing, which incentivized early renewals regardless of feature utility. Furthermore, customer enthusiasm was solicited after being told the feature is the "centerpiece" of the roadmap, creating a confirmation bias that masks actual usage patterns. The Demand Cleanroom is the only intervention that isolates the product's value from these external drivers by removing the price incentive and the roadmap pitch.

The Adoption Quality Sprint merely tracks behavior without explaining why analysts abandon the tool or why managers use it for samples rather than live cases. The Case Evidence Review provides a snapshot of utility but cannot determine if that utility is sufficient to drive revenue or prevent the churn already signaled by regional administrators.

**Strongest reason against:**
This approach risks short-term revenue volatility and may alienate the sales team by removing their most effective closing tools (the bundle price and roadmap vision) during a critical budget window.

**Evidence that would change my mind:**
If the Demand Cleanroom reveals that expansion intent and renewal speed remain stable—or increase—despite the removal of bundle pricing and roadmap promises, it would prove the product has genuine market pull. Conversely, if "non-pitched" accounts show a significant spike in objections or slower closing rates compared to the matched set, it would confirm that the current growth is a sales-driven illusion, necessitating a pivot toward fixing the core workflow (as seen in the public-sector abandonment) before any further scaling.

================  OUT-29  ================

---
anonymous_label: OUT-29
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 9228593b78f01ffbede9089b327fbb652896445a1e9b0cf75d5c05c4010f7ee9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-29

I recommend the **Case Evidence Review**.

### The Recommendation
You should advise the CEO to commit to the Case Evidence Review. While the executive team is celebrating "commercial discipline," your data suggests you are currently experiencing a **false positive**.

The expansion bookings were driven by pricing incentives (the bundle), not product value. The usage spike is "vanity usage" (managers rehearsing samples) rather than "value usage" (analysts solving cases). Most critically, you have a looming retention cliff with regional administrators and a fundamental "explainability" failure in the public sector.

Scaling now would be scaling an unstable foundation; the Adoption Quality Sprint only tracks *if* they use it, not *why* they stop; and the Demand Cleanroom tells you if people will pay for it, but not how to fix the product so they *want* to keep paying for it. You must determine if PlanPilot is actually solving the workflow problem or if it is simply a sophisticated drafting tool that analysts abandon once the "newness" wears off.

### The Strongest Reason Against It
**Velocity and Executive Optics.** This is the slowest, most manual of the three validation options. After a "surprisingly strong quarter," the executive team is in a celebratory mood and feels they have found the winning formula. Recommending a deep-dive audit into "overridden" and "impossible to explain" suggestions feels like applying the brakes during a sprint. It risks painting the product team as overly cautious or "academic" at a moment when Sales wants to capitalize on momentum.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "impossible to explain" feedback is limited strictly to a tiny, idiosyncratic subset of public-sector users and that the "manual notes" fallback used by analysts is actually a preference for documentation style rather than a failure of the tool's logic. If the product is fundamentally sound and the friction is merely a "sales packaging" or "training" issue, you don't need to audit the cases—you need to test if the market will pay full price without the bundle.

================  OUT-30  ================

---
anonymous_label: OUT-30
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 959577fbc023e1ecad749f9a2e13f10fce0d9cecf6f618d3b024b6fb593547cd
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-30

I recommend that you commit to the **Case Evidence Review**.

### Why this recommendation?
Your current success is "entangled," meaning the positive lagging indicators (expansion bookings, shortened sales cycles) are likely being driven by sales incentives and roadmap promises rather than actual product value. You have a critical "signal" problem:
1. **Financials are skewed:** The expansion is tied to temporary bundle pricing (price-driven, not value-driven).
2. **Usage is misleading:** High frequency is driven by managers practicing on closed samples, not analysts solving live problems.
3. **The "Value Gap" is visible:** Analysts abandon the tool when they cannot explain the logic to reviewers (the "black box" problem).

The *Adoption Quality Sprint* measures *if* people use it, and the *Demand Cleanroom* measures if people *buy* it, but neither tells you *why* the product is failing in the actual workflow. The Case Evidence Review is the only option that audits the "job to be done." By identifying exactly which suggestions are overridden or impossible to explain, you move from guessing about "enablement" to identifying specific product failures in the logic engine.

### The strongest reason against it
This approach is slow and qualitative. It provides a "snapshot" of past behavior rather than a real-time experimental result. While you are reviewing case files, the Sales team may continue to sell a version of PlanPilot that doesn't actually work for the end-user, potentially increasing the "churn debt" you will have to pay when those regional administrators' procurement windows finally close.

### Observable evidence that would change my mind
I would switch to the **Demand Cleanroom** if you discovered that the "impossible to explain" feedback was limited strictly to the public sector, while private-sector analysts showed high "acceptance/no-override" rates in their workflows. If the product is fundamentally sound for 80% of your market and the only issue is a sales-led pricing bubble, you need to validate commercial demand (the Cleanroom) rather than refine the product logic.

================  OUT-31  ================

---
anonymous_label: OUT-31
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 96c399bfa5c8f542659c5d72c6a6e75327781eaa804fe7d5d767caf7b08fbf86
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-31

I recommend the **Case Evidence Review**.

### The Recommendation
You should advise the CEO to commit to the Case Evidence Review. While the financial metrics look strong, they are currently "noisy"—inflated by temporary pricing bundles and skewed by sales narratives. The core risk is that you have built a tool that managers *like* (for oversight) but analysts *distrust or cannot use* (for execution).

The Case Evidence Review is the only option that penetrates the "black box" of the actual workflow. By analyzing whether suggestions are accepted, overridden, or unexplainable, you move from measuring **activity** (which is currently vanity-driven by managers rerunning samples) to measuring **efficacy**. This provides the only reliable foundation for next year's budget: knowing if PlanPilot is a scalable value-driver or a polished demo that fails under operational scrutiny.

### The Strongest Reason Against It
The Case Evidence Review is a "slow" qualitative audit in a high-pressure quantitative environment. It does not provide the immediate, boardroom-ready "green light" that a Demand Cleanroom (sales validation) or an Adoption Quality Sprint (usage data) offers. By choosing this, you are sacrificing the ability to prove immediate commercial demand or rapid usage growth to the board in twelve days; you are choosing operational truth over perceived momentum.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the two regional administrators planning to remove PlanPilot did so because of **pricing/budgetary constraints** rather than **product utility**.

If the "churn" is purely financial, your problem is a pricing strategy issue (solved by the Cleanroom). However, if the churn—and the public-sector abandonment—is because the tool is a "black box" that analysts cannot defend to their reviewers, you have a fundamental product-market fit failure. Given the current evidence of analysts falling back to manual notes and public-sector abandonment, the risk is likely utility, not price.

================  OUT-32  ================

---
anonymous_label: OUT-32
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 9d5263adbcdf6dbc0ab63347c5194d77d246cb831634adb3f655ff36ea29e85f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-32

**Recommendation:** Commit to the **Case Evidence Review**.

**Why:**
Your current success is "entangled," meaning your positive commercial signals (expansion bookings, shortened cycles) are likely confounded by temporary pricing bundles and sales narratives rather than product value. The usage data is equally ambiguous: high frequency by managers does not equal utility for the front-line analysts who actually drive the workflow.

The Case Evidence Review is the only proposal that addresses the "Jobs-to-be-Done" (the actual utility of the renewal action plans). By inspecting whether suggestions are accepted, overridden, or impossible to explain, you move from *proxy metrics* (usage percentages and support tags) to *direct evidence* of product-market fit. Scaling now would be premature, and the Adoption Quality Sprint merely tracks behavior without explaining why analysts abandon the tool or why public-sector users cannot justify its output. The Demand Cleanroom tests sales elasticity, but it doesn't tell you how to fix the product if the value proposition is fundamentally flawed.

**The strongest reason against it:**
This approach is slow and qualitative. It ignores the immediate commercial momentum and risks "analysis paralysis" while competitors may move faster. By choosing a retrospective review over the Demand Cleanroom or scaling, you are prioritizing product integrity over short-term revenue optimization and may miss a window to capture expansion dollars while the "halo effect" of the launch is still strong.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" results (should they be run) show that buyers are willing to pay full price for PlanPilot *without* the roadmap pitch or bundle discounts, it would indicate that the perceived value is already high enough to sustain growth despite the current workflow friction. In that case, I would shift the recommendation to "Scale PlanPilot Broadly," as the commercial pull would outweigh the need for immediate workflow refinement.

================  OUT-33  ================

---
anonymous_label: OUT-33
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 9df51135155ee75fa159246c8d9d4b576f89d5190bebd1dadc57b52c21c07fee
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-33

I recommend that the CEO commit to the **Demand Cleanroom**.

### Reasoning
The current perception of success at Brightwell Benefits is likely a result of the **halo effect** (BK-0048-card-001). Because overall performance is currently strong—expansion bookings are up 16% and renewals are closing early—the executive team is attributing this success to specific traits of the product team (e.g., "commercially disciplined," "aligned around the right buyer"). However, the evidence suggests these trait assessments are not independent of the performance signal:
*   **Financial Noise:** The expansion growth is heavily tied to temporary bundle pricing (a financial incentive), not necessarily product value.
*   **Narrative Bias:** Customer enthusiasm was collected after sales teams pitched PlanPilot as a "roadmap centerpiece," meaning the feedback is based on future promise rather than current utility.
*   **Hidden Churn:** Regional administrators are already planning to remove the feature, a signal that is currently invisible in official churn reporting.

To establish a "real strategy" (BK-0001-card-001), the CEO needs a **diagnosis** based on facts rather than halo-tinted impressions. The Demand Cleanroom is the only proposal that isolates the product's actual value from the noise of pricing incentives and sales narratives. By removing the bundle offers and the roadmap pitch, you can determine if PlanPilot is actually driving expansion or if it is simply a passenger on a wave of financial engineering.

The other options fail this diagnostic need:
*   **Adoption Quality Sprint:** Measures "activity" and "enablement," which Ries warns are often vanity measures that do not equal **validated learning** (BK-0007-card-001).
*   **Case Evidence Review:** Provides qualitative insight into usage, but does not resolve whether the product is a commercial driver or a subsidized add-on.
*   **Scaling Broadly:** This would be "executing a plan" without validated learning, risking massive waste if the current growth is illusory.

### The Strongest Reason Against This Recommendation
The Demand Cleanroom creates immediate **short-term revenue risk**. By stopping bundle-price offers and withholding the roadmap pitch, you may intentionally slow down expansion bookings or extend sales cycles in the current quarter. In a board-driven environment, sacrificing "green" metrics to find "true" metrics is often perceived as an unnecessary risk to the current momentum.

### Evidence That Would Change My Mind
I would change this recommendation if you could produce evidence of **validated learning** (BK-0007-card-001) that is independent of the financial incentives. Specifically, if you could show a cohort of customers who **did not** receive bundle pricing and **did not** hear the roadmap pitch, yet still increased their spend or renewed early specifically citing PlanPilot's utility. If that independent evidence already exists, the Demand Cleanroom is redundant, and you could safely move to scaling or deepening the product's specific workflows.

================  OUT-34  ================

---
anonymous_label: OUT-34
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 9f13f8e55479ec9b1506e62ff9ccb55b68a244ef4eadf7c9ceb21c2a198fc391
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-34

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a classic "false positive" signal. Your executive team sees growth (expansion bookings, shortened cycles) and attributes it to product-market fit. However, the granular data suggests this growth is driven by **sales incentives** (bundle pricing) and **buyer aspiration** (the roadmap pitch), rather than **user utility**.

The risk is that you are scaling a "leaky bucket." The evidence of analysts falling back to manual notes, the inability of public-sector users to explain recommendations, and the quiet churn in regional accounts indicate that PlanPilot is currently a "management tool" (used for enablement and reviews) rather than a "workflow tool" (integrated into the analyst's daily habit).

Here is why the other options are insufficient or dangerous:
*   **Scale PlanPilot Broadly:** This is high-risk. If the core utility is missing, scaling will only accelerate churn once the "bundle price" honeymoon ends.
*   **Adoption Quality Sprint:** This measures *what* is happening (event tracking) but not *why*. You already know the usage patterns are skewed toward managers; more dashboards won't tell you why analysts abandon the tool.
*   **Demand Cleanroom:** This tests sales elasticity, not product value. It tells you if the product is sellable without discounts, but it doesn't tell you how to fix the product so that users actually keep it.
*   **Narrow to Public Sector:** This is premature. The public sector has specific "explainability" hurdles, but you don't yet know if the core engine is failing across all segments or just that specific one.

The **Case Evidence Review** is the only option that addresses the "truth gap." By auditing actual case files, you move from *proxy metrics* (usage pings) to *outcome metrics* (accepted vs. overridden suggestions). This reveals whether the "strong quarter" was a result of a great product or a great sales motion.

### The Recommendation
**Commit to the Case Evidence Review.** Use the next twelve days to define the sample set and the rubric for "accepted/overridden/impossible." This provides the empirical basis to decide—mid-year—whether to pivot the roadmap or double down on scaling.

### The Strongest Reason Against It
The Case Evidence Review is slow, manual, and "un-sexy" compared to the growth metrics the board currently loves. By choosing this, you are effectively telling the CEO and Board: *"The recent growth might be an illusion."* This risks damaging the current momentum and political capital the product team has gained by being seen as "commercially disciplined." You are trading a high-growth narrative for an uncomfortable truth.

### Observable Evidence That Would Change My Mind
I would switch my recommendation to **Scale PlanPilot Broadly** if you can produce evidence that the "manual notes" fallback is not a failure of the tool, but a requirement of the industry's compliance standards.

Specifically: if you find that analysts *do* accept PlanPilot’s recommendations but are *required* to transcribe them into manual notes for legal auditing purposes, then the product is already providing value—it just needs a "export to audit log" feature. In that case, the utility is proven, and you should scale immediately.

================  OUT-35  ================

---
anonymous_label: OUT-35
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: a6c85632443b1430f3e49889103371a3ca187a19b16e97bc6c406ff73f08bb15
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-35

**Recommendation:** Run the Demand Cleanroom.

**Reasoning:** The current growth signals are heavily contaminated by financial incentives and sales narratives rather than product value. Expansion bookings rose, but the data reveals these gains were driven by temporary bundle pricing (a financial lever) and promises of future roadmap items (a sales narrative), not the utility of the existing feature. The "enthusiastic" feedback is non-independent, as it was collected immediately after sales teams pitched PlanPilot as the future of the product. Meanwhile, usage data is misleading: high activity is driven by managers practicing on old samples rather than analysts solving live problems. The Demand Cleanroom is the only intervention that isolates the product's actual market pull by removing these confounding variables. It reveals whether customers will pay for what exists today without the lure of discounts or future promises.

**Strongest Reason Against:** This approach risks short-term revenue volatility and may alienate the sales team. By removing bundle pricing and roadmap pitches, you may see a drop in expansion bookings or an increase in renewal objections in the short term, which could create friction with executives who are currently celebrating a "strong quarter."

**Evidence that would change my mind:** If the Case Evidence Review were to reveal that analysts are overriding or rewriting more than 50% of PlanPilot’s suggestions, the Demand Cleanroom would be a waste of time. In that scenario, the problem is not "demand" or "pricing," but a fundamental failure of the core logic. If the product doesn't actually work for the end-user, testing whether they will pay for it is irrelevant; you would instead need to pivot the plan toward fixing the workflow or narrowing the focus to a specific segment.

================  OUT-36  ================

---
anonymous_label: OUT-36
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: b1f6c5ce0a9e43082bcb15f8cafc7fe344984667c59a13571f3c83ecfcd2af00
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-36

**Recommendation: Run the Demand Cleanroom.**

The current growth metrics are contaminated by financial incentives and sales narratives. The 16% rise in expansion bookings is tied to temporary bundle pricing, meaning the revenue reflects a discount-driven timing shift rather than an increase in perceived value. Furthermore, customer enthusiasm was collected after being told the feature is the future of the roadmap, which creates a confirmation bias where buyers signal agreement with a vision rather than satisfaction with a tool. This intervention is the only one that isolates whether buyers will pay for the product based on its current utility without the influence of pricing lures or future promises.

**Strongest Reason Against:**
This approach risks short-term revenue volatility and may create friction with the sales team. By removing bundle pricing and the roadmap pitch, you may see a dip in expansion bookings or longer renewal cycles in the immediate term, which could be perceived by leadership as a loss of momentum just before budget locking.

**Evidence that would change this recommendation:**
If the Case Evidence Review were to reveal that front-line analysts are not just ignoring PlanPilot, but are actively producing outcomes that are fundamentally safer or more accurate than the software's suggestions, the problem would be a core product failure rather than a demand-generation illusion. In that case, testing pricing (Demand Cleanroom) would be irrelevant because the product lacks a viable value proposition to sell.

================  OUT-37  ================

---
anonymous_label: OUT-37
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: c084e34928e8a7de886a888ebfb7be6aaf199a13795a879183894661d0bb6a27
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-37

I recommend that you commit to the **Case Evidence Review**.

**Why:**
The current "strong quarter" is built on fragile, lagging indicators. Expansion revenue is skewed by temporary pricing bundles rather than organic value, and usage spikes are driven by managers reviewing old samples (administrative overhead) rather than analysts solving live problems. Most critically, you have a "black box" problem: public-sector users are abandoning the tool because they cannot explain the logic to reviewers, and analysts revert to manual notes after two days.

Before scaling or testing demand, you must determine if PlanPilot is actually providing a correct and usable output or if it is simply a "drafting tool" that analysts find too risky or opaque to rely on. The Case Evidence Review is the only option that provides a ground-truth audit of whether the product's core value proposition (proposed renewal action plans) is actually being accepted or overridden in practice.

**The strongest reason against it:**
This approach prioritizes product integrity over immediate commercial momentum. By choosing a qualitative review over the Demand Cleanroom or broad scaling, you risk ignoring the "commercial discipline" praised by the executive team. If the product is "good enough" and the current friction is purely an enablement/training issue, spending time on a case review may be seen as over-engineering the solution while leaving revenue on the table.

**Observable evidence that would change my mind:**
I would pivot to the **Demand Cleanroom** if you discovered that the "removal" requests from regional administrators were driven entirely by price sensitivity (the loss of the bundle) rather than a lack of perceived value. If the evidence showed that buyers were willing to pay full price for a tool they didn't fully understand, the primary risk would shift from "product utility" to "pricing strategy," making the Cleanroom the higher-priority validation.

================  OUT-38  ================

---
anonymous_label: OUT-38
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: c2fb63130675c35376a7da25b873d5c05dc7ac1a3a710563e0919bcf9ede6130
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-38

**Recommendation**
Run the Demand Cleanroom.

**Reasoning**
The current growth signals are contaminated by financial incentives and sales narratives rather than product value. The 16% rise in expansion bookings is tied to temporary bundle pricing, meaning the revenue reflects a discount-driven deadline rather than an increase in perceived utility. Furthermore, customer enthusiasm was collected after being told the feature is the future of the roadmap, which creates a confirmation bias in buyer comments.

The usage data is equally deceptive: high frequency is driven by managers practicing on closed cases (non-productive use), and analysts abandon the tool once the initial rollout ends or when they face internal scrutiny. The "drop" in support tickets is likely a reporting shift to training channels, not an increase in accuracy. The Demand Cleanroom is the only intervention that isolates whether buyers will pay for the current functionality without the influence of price bundles or future promises. The Adoption Quality Sprint merely tracks symptoms of a potential failure, and the Case Evidence Review looks at accounts that have already signed, failing to test if the product actually drives the renewal decision.

**Strongest Reason Against**
This approach creates a high short-term risk of slowing expansion bookings and may alienate the sales team by removing their most effective closing tools (discounts and roadmap promises) right before a budget lock.

**Evidence That Would Change My Recommendation**
If the Case Evidence Review reveals that a significant majority of PlanPilot suggestions in renewed accounts were accepted without manual rewriting, it would prove the tool provides objective value regardless of how it was sold. In that case, the priority would shift from validating demand to fixing the "explainability" gap for users.

================  OUT-39  ================

---
anonymous_label: OUT-39
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: c31da3410c33e143ef894be27d3859de818192badf37d7896bec9d35b19688b6
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-39

**Recommendation:** Run the Case Evidence Review.

**Why:** Your current success is "entangled," meaning your lagging indicators (expansion bookings, shortened sales cycles) are likely being driven by sales incentives and the "Halo Effect" of a new roadmap pitch rather than actual product value. The usage data is equally deceptive: high frequency is driven by managers (not the primary users) and initial novelty, while the public sector reveals a critical failure in "explainability."

Scaling now would be betting on a facade. The Adoption Quality Sprint tracks *behavior* (return rates), but not *value* (whether the plan was actually used to solve a problem). The Demand Cleanroom tests *willingness to pay*, but not *product efficacy*. Only the Case Evidence Review identifies the "Jobs to be Done" (per Christensen) by revealing exactly where the software provides a useful output versus where it is being manually overridden or ignored. You must determine if PlanPilot is a functional tool or a sales ornament before committing next year's budget to scaling it.

**The strongest reason against this:** It is the slowest and most manual of the three validation options. In a twelve-day window before the board locks the budget, this qualitative deep dive provides less "hard data" for a slide deck than a Demand Cleanroom or an Adoption Sprint, potentially making the product team look hesitant or unable to quantify success to a bullish executive team.

**Observable evidence that would change my mind:** If the "wrong recommendation" tickets in the training channel showed a statistically significant decline across all segments (including public sector) and were accompanied by verified logs showing that front-line analysts are sticking with the tool *after* the first two days of rollout without manager intervention. This would suggest the "explainability" gap is a training issue rather than a fundamental product failure, shifting the priority toward the Adoption Quality Sprint.

================  OUT-40  ================

---
anonymous_label: OUT-40
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: c4780f5fd30d69d0e4debe66c90642487a3967113ad9c44918d3009912b221e0
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-40

I recommend the **Demand Cleanroom**.

### The Recommendation: Demand Cleanroom
You should recommend the Demand Cleanroom to the CEO. This is the only option that isolates whether your strong quarter was driven by product value or by temporary financial incentives and sales narratives.

The current "success" signal is heavily contaminated by the **halo effect** (BK-0048-card-001). Because expansion bookings rose and renewals closed early, leadership is now attributing specific traits to the product team—describing them as "focused," "commercially disciplined," and "aligned." However, the evidence suggests these trait assessments are reflections of the performance signal rather than independent evidence: expansion dollars were driven by temporary bundle pricing, and customer enthusiasm was gathered after sales pitched PlanPilot as a future centerpiece.

Without the Demand Cleanroom, you are risking a "scale broadly" decision based on halo-tinted data. The Cleanroom provides the necessary empirical evidence to determine if buyers value PlanPilot itself or merely the discount and the promise of a roadmap.

### The Strongest Reason Against It
The Demand Cleanroom creates immediate friction with the Sales organization and risks a short-term dip in expansion bookings for the matched set of accounts. By removing bundle pricing and withholding the roadmap pitch, you are intentionally removing the two primary levers that drove the "surprisingly strong quarter." In a high-pressure environment with a board meeting in twelve days, this may be perceived as sabotaging momentum or "fighting" the sales team during a winning streak.

### The Observable Evidence That Would Change My Mind
I would change this recommendation to the **Case Evidence Review** if you could provide evidence that the primary driver of the current growth is not the bundle pricing, but a high "acceptance rate" of PlanPilot’s core logic.

Currently, your usage data is a "vanity metric" (BK-0007-card-001): high frequency is driven by managers rerunning samples for meetings, not analysts using the tool to solve cases. If a preliminary audit showed that front-line analysts were keeping PlanPilot suggestions intact (rather than manually rewriting them or abandoning the tool in the public sector), it would suggest the product has "validated learning" (BK-0007-card-001) regarding its value proposition. In that case, the risk shifts from "do they want it?" to "how do we make it usable?", making the Case Evidence Review the higher-leverage move.

================  OUT-41  ================

---
anonymous_label: OUT-41
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: c939a2e3ce6573a6645e804ff6329395d1b3a90987c233443d7e037f176145d4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-41

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" signal. Your revenue metrics (expansion bookings, shortened cycles) are contaminated by sales incentives—specifically the bundle pricing and roadmap promises. You cannot trust the financial data to tell you if PlanPilot is providing actual value or if Sales is simply selling a vision.

The usage data is equally ambiguous. A 39% increase in usage is meaningless if the activity is "rerunning samples" (training/demo behavior) rather than solving live production cases. The most alarming signal is the "explainability gap" in the public sector and the analysts falling back to manual notes. This suggests that while PlanPilot can generate a *plausible* draft, it may not be generating a *defensible* one. In B2B workflow software, if a user cannot defend the output to their boss or a regulator, the tool is a liability, not an asset.

**Why not the other options?**
*   **Scale PlanPilot Broadly:** This is the highest-risk move. You have evidence of "silent churn" (the regional administrators) and a lack of analyst stickiness. Scaling now would likely accelerate churn once the bundle pricing expires.
*   **Adoption Quality Sprint:** This measures *behavior*, not *value*. You already know the behavior (analysts use it for two days, then stop). More dashboards won't tell you *why* they stop or if the output is actually wrong.
*   **Demand Cleanroom:** This tests *willingness to pay*, but you don't yet know if the product actually *works* for the end-user. If the product is fundamentally flawed in its logic, a cleanroom only tells you how much you can charge for a flawed product.
*   **Narrow to Public Sector:** This is premature and potentially a mistake, as the public sector currently shows the *worst* adoption due to explainability requirements.

The **Case Evidence Review** is the only option that attacks the "ground truth." By auditing actual files, you move from proxy metrics (clicks and bookings) to outcome metrics (accepted vs. overridden). This tells you if the product is a "productivity booster" or just a "fancy first draft" that requires manual correction.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow, qualitative, and "unsexy" to a board that is currently celebrating a strong quarter. It provides no immediate revenue lift and requires manual labor from your most valuable customers. By choosing this, you are effectively telling the CEO: *"The strong quarter might be an illusion created by Sales; we need to stop celebrating and verify the product's utility before we bet next year's budget on it."* This may be perceived as a lack of confidence or "product perfectionism" in the face of commercial momentum.

### Evidence That Would Change My Mind
I would pivot to **Scaling Broadly** if the "silent churn" from the regional administrators was revealed to be unrelated to PlanPilot (e.g., a budget cut or a competitor's move) AND if the "manual notes" behavior was proven to be a preference for hybrid workflows rather than a lack of trust in the tool's accuracy. If you found that 80%+ of PlanPilot suggestions were accepted without modification in the first few audits, the "explainability" issue is a training problem, not a product problem, and you should scale immediately.

================  OUT-42  ================

---
anonymous_label: OUT-42
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: ccee77b0ea11b5dfb3d2fcab5b6808dabacbb9e52a0f8a28b95de4a6ab7a7657
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-42

I recommend that you commit to the **Case Evidence Review**.

**Why:**
The current success is "entangled" and potentially illusory. Your financial gains are skewed by temporary bundle pricing (incentivizing speed over value), and your usage metrics are inflated by managers rerunning old samples rather than analysts solving live cases. Most critically, the "silent churn" from regional administrators and the abandonment in the public sector suggest a fundamental gap between the tool's output and the user's ability to execute or justify that output.

The Adoption Quality Sprint measures *if* they return, and the Demand Cleanroom measures *if* they will pay without a discount, but neither tells you *why* the product is failing in the workflow. The Case Evidence Review is the only option that exposes the "black box" of the product's utility by identifying exactly where suggestions are overridden or impossible to explain. You cannot scale a product—or accurately forecast its revenue—if you don't know if the core value proposition is actually functioning at the analyst level.

**The strongest reason against it:**
It is a slow, manual, and qualitative process. Unlike the Adoption Quality Sprint or Demand Cleanroom, it does not provide a clean "yes/no" metric for the board. In a twelve-day budget window, the executive team may perceive this as "academic" research that lacks the immediate commercial urgency of a sales-led validation test.

**Observable evidence that would change my mind:**
If the "wrong recommendation" support tickets—including those currently hidden in the training channel—show a statistically significant and consistent trend of simple UI/UX friction rather than logic errors, I would switch to the **Adoption Quality Sprint**. If the problem is merely "how to use it" (enablement) rather than "what it tells me" (utility), then tracking return rates and cleaning up enablement is the faster path to stabilizing retention.

================  OUT-43  ================

---
anonymous_label: OUT-43
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: cec4a7556669c4472781f1272fd7b63de95f4be43422faac7a4e22f796518a92
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-43

**Recommendation:** Run the **Case Evidence Review**.

**Why:**
The company is currently experiencing a "Halo Effect" (per Rosenzweig), where strong financial metrics—driven by temporary pricing bundles and sales optimism—are masking fundamental product-market fit issues. The current data is "entangled": usage is high, but the *nature* of that usage (managers rerunning samples for meetings) does not indicate value creation for the primary user.

The Case Evidence Review is the only proposed option that addresses the "Jobs to be Done" (per Christensen) for the front-line analyst. The evidence suggests a critical failure in "explainability" (especially in public sector) and a regression to manual notes. Without knowing *why* suggestions are overridden or impossible to explain, scaling the product is a risk, and the Adoption Quality Sprint (which measures *if* they return) will not explain *why* they are failing. The Demand Cleanroom measures sales appetite, but the current data suggests that while buyers *want* the vision, users are struggling with the utility. You must validate the core value proposition at the workflow level before committing next year's budget to scaling.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation tests. Unlike the Adoption Quality Sprint (which relies on automated event tracking) or the Demand Cleanroom (which relies on sales outcomes), a Case Evidence Review requires manual, qualitative analysis of files and interviews. In a twelve-day window before the board locks the budget, this method provides the least "instant" quantitative gratification for an executive team currently riding a wave of expansion bookings.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" were to reveal that buyers are willing to pay a significant premium for PlanPilot *specifically* because it solves the "explainability" problem for their internal reviewers (meaning the value is perceived as a compliance/audit tool rather than a productivity tool), I would pivot to scaling the product. If the demand is driven by the *existence* of an automated plan rather than the *accuracy* or *utility* of that plan, the product risk is lower and the commercial opportunity takes precedence.

================  OUT-44  ================

---
anonymous_label: OUT-44
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: dbb49789b3b48babfc019649e14e18be54a1a635e1dc6669e56cd45724c716b4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-44

**Recommendation: Run the Demand Cleanroom.**

The current growth metrics are contaminated by temporary pricing incentives and a sales pitch that sells a future roadmap rather than the current product's value. The rise in expansion bookings is likely a reflection of financial engineering (the bundle price) and anticipation of future features, not the utility of the existing tool. Because regional administrators are already seeking to remove the feature and public-sector users cannot justify its outputs, there is a high risk that the "strong quarter" is a lagging indicator of sales effort rather than a leading indicator of product-market fit. The Demand Cleanroom is the only intervention that isolates whether customers will pay for what exists today without the distortion of discounts or promises.

**Strongest reason against:** This approach risks short-term revenue. By removing bundle pricing and roadmap pitches, you may slow the current momentum of expansion bookings and extend sales cycles in the immediate term, which could be perceived as a failure by an executive team currently celebrating "commercial discipline."

**Observable evidence that would change my mind:** If the Case Evidence Review (which I am sacrificing) were to reveal that analysts are manually rewriting 90%+ of the plans but still renewing because the "starting point" saves them significant time, it would prove the product has foundational utility despite poor output quality. In that scenario, the problem is a usability gap rather than a demand gap, making the Adoption Quality Sprint or Case Evidence Review more valuable than testing price sensitivity.

================  OUT-45  ================

---
anonymous_label: OUT-45
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: e158f275d461bbf17d4296c55de15b2e6922441ea4deff47c32e332b5906c468
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-45

**Recommendation:** Run the Case Evidence Review.

**Why:** Your current success is "entangled," meaning your lagging indicators (expansion bookings and shortened sales cycles) are likely being driven by temporary pricing incentives and the *promise* of a roadmap rather than the actual *value* of the product. The usage data is equally deceptive: high frequency among managers (who aren't the primary users) and early-stage spikes among analysts who then abandon the tool.

The core risk is a "value gap"—specifically, the inability of analysts to explain recommendations to reviewers (critical in public sector) and a reliance on manual notes. The Adoption Quality Sprint tracks *if* they use it, and the Demand Cleanroom tracks *if* they will pay for it, but neither explains *why* it is failing in the workflow. The Case Evidence Review is the only option that provides a ground-truth audit of the product's utility. By seeing exactly what was overridden or rewritten, you can determine if PlanPilot is a genuine productivity booster or merely a "drafting tool" that creates more work for the analyst to fix.

**The strongest reason against it:** This is a qualitative, slow-velocity approach that does not provide the "hard" financial or behavioral data (like churn or conversion rates) that a Board typically demands during budget locking. It risks being viewed as "academic" while the Sales team is currently winning deals based on the product's perceived momentum.

**Observable evidence that would change my mind:** If the "Demand Cleanroom" results were to show that expansion bookings remain high and renewal objections remain low even *without* the bundle pricing and roadmap pitches. This would prove that the market value is decoupled from the workflow friction, suggesting that the "perceived value" is high enough to sustain growth regardless of the internal analyst struggle.

================  OUT-46  ================

---
anonymous_label: OUT-46
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: e18b79dcd3f976531a47d5f0f684f9728deeefd8f15fba9db2d1a18739f075b4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-46

**Recommendation**

Run the Demand Cleanroom.

**Reasoning**

The current growth indicators are heavily contaminated by temporary financial incentives and sales messaging rather than product utility. The 16% rise in expansion bookings is tied to bundle pricing, and the "enthusiastic" feedback was collected after sales promised a future roadmap, creating a confirmation bias.

The usage data is misleading: high activity is driven by managers practicing on closed samples (non-productive use) and analysts who abandon the tool once initial novelty fades or when they face internal scrutiny. The decline in "wrong recommendation" tickets is likely an artifact of users shifting their complaints to training channels, hiding the actual error rate.

The Case Evidence Review would show that analysts are overriding the tool, but it wouldn't prove if customers would pay for it without a discount. The Adoption Quality Sprint focuses on "cleaner enablement," which assumes the product is fundamentally valuable and only needs better training—a dangerous assumption given that public-sector users cannot explain the logic to reviewers. Only the Demand Cleanroom isolates whether there is organic commercial demand for PlanPilot's current state, stripped of pricing lures and future promises.

**Strongest Reason Against**

This intervention creates immediate commercial risk. By withholding bundle pricing and the roadmap pitch, you may intentionally slow down current quarter velocity or trigger objections in a high-stakes renewal window, potentially upsetting the sales team and creating a temporary dip in expansion bookings.

**Evidence that would change this recommendation**

If the Case Evidence Review were modified to include a "willingness-to-pay" survey for those who accepted the suggestions without overrides, and that data showed a high percentage of analysts would personally advocate for the budget regardless of bundle pricing, I would pivot to the Case Evidence Review. This would prove the value is realized at the user level, making the sales-tactic test redundant.

================  OUT-47  ================

---
anonymous_label: OUT-47
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: e1f6932fe30a5326d6a318936a3fc19a697b9fa14b318d88c5caec55a535270d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-47

I recommend you commit to the **Case Evidence Review**.

### The Recommendation
You must prioritize the Case Evidence Review over all other options. While your executive team sees "commercial discipline," the underlying data suggests you have a **value-perception gap**.

The current growth is likely an artifact of pricing bundles and sales narratives (the "roadmap pitch") rather than product utility. The usage spikes are "vanity metrics": managers using the tool for internal enablement and analysts using it as a starting template before reverting to manual work. Most critically, the public sector abandonment reveals a failure in "explainability"—the tool provides an answer, but not the *rationale* required for a professional benefits administrator to defend that action to a reviewer.

The Case Evidence Review is the only proposal that looks at the **actual work product** (the case files). It will reveal whether PlanPilot is actually solving the complex benefits problem or simply providing a "draft" that analysts spend more time fixing than they would have spent creating from scratch.

### The Strongest Reason Against It
The Case Evidence Review is a slow, qualitative "manual" process that provides no immediate revenue signal. Unlike the Demand Cleanroom (which tests pricing power) or the Adoption Quality Sprint (which provides clean dashboards), this review will not give you a "green light" for scaling. It is likely to uncover uncomfortable truths—that the product is being overridden or rewritten—which could deflate the current executive optimism and create friction with a Sales team that is currently riding a wave of expansion bookings.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discover that the "bundle price" was not a primary driver of renewal, but rather a minor incentive. If evidence emerges that customers are signing expansion agreements *specifically* because of the PlanPilot functionality—despite the lack of explainability and the reliance on manual overrides—it would indicate that the "perceived value" (the prestige of having an AI-driven plan) is higher than the "actual utility." In that specific scenario, you have a marketing win rather than a product failure, and the priority shifts to testing price elasticity rather than fixing workflow integration.

================  OUT-48  ================

---
anonymous_label: OUT-48
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: eb141fa090a0da7e883b413a0e57eb39cc7ea4bae1d0be976e7ec70a8ddca98c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-48

I recommend that you commit to the **Demand Cleanroom**.

### Recommendation: The Demand Cleanroom
You should recommend this package because your current "strong quarter" is heavily contaminated by the **halo effect** (BK-0048-card-001). The executive team is attributing the rise in expansion bookings to the product team's "focus" and "discipline," but the evidence suggests these traits are being re-coded to fit a positive performance signal.

The data indicates that the financial success is likely driven by a temporary bundle price (a pricing lever) and a roadmap pitch (an aspirational promise), rather than the actual utility of PlanPilot. Because the performance outcome is visible first, leadership has developed a favorable impression of the product team's attributes. To avoid scaling a product based on "halo-tinted" evidence, you must isolate the demand. The Demand Cleanroom is the only proposal that removes the confounding variables—the pricing incentive and the roadmap narrative—to determine if there is an independent, sustainable desire for PlanPilot.

### The Strongest Reason Against It
The primary risk is the immediate impact on short-term revenue. By stopping bundle-price offers and withholding the roadmap pitch, you are intentionally removing the two strongest catalysts for closing renewals quickly. If the board is primarily focused on maintaining the current growth trajectory for the next twelve days or the immediate following quarter, this "cleanroom" approach will appear to be a deliberate sabotage of the sales pipeline.

### Observable Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence of **validated learning** (BK-0007-card-001) that is independent of the sales process.

Currently, your usage data is a "vanity metric": high-frequency activity from managers rerunning samples and short-term bursts from analysts do not prove the product is solving a core problem. If you had evidence—such as the "Case Evidence Review" results showing that analysts are consistently accepting and acting on PlanPilot suggestions without manager oversight—it would prove the product has intrinsic value. If you can demonstrate that customers are behaving in a way that proves they value the *output* of the tool rather than the *price* of the bundle, the need for a Demand Cleanroom vanishes in favor of scaling.
